EBD GmbH is part of the Knowledge & Networking Division of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
 
Biotech Showcase 2015 EBD Group Demy-Colton
Share/Follow Us
Share this:
Follow this event:

Preliminary List of Biotech Showcase™ 2016 Presenting Companies

Please note, company presentation times are subject to change, so please check back often.

Click on any row to see more company information

ABIVAX
ABIVAX
(EURONEXT:ABVX)
Paris, France
ABIVAX is an emerging leader in the discovery, development and commercialization of anti-viral therapies and therapeutic vaccines to treat life-threatening infectious diseases...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ABIVAX

ABIVAX is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 10:30 am. Room Mission II.
ABIVAX
Track: C
City: Paris
Country: France
Ownership: Public
Ticker: ABVX
Stock exchange: EURONEXT
ABIVAX is an emerging leader in the discovery, development and commercialization of anti-viral therapies and therapeutic vaccines to treat life-threatening infectious diseases. ABIVAX has 2 compounds in clinical trials: ABX464, a first-in-class, long-acting oral small molecule HIV/AIDS therapy; and ABX203, a therapeutic vaccine for immunotherapy of chronic hepatitis B.

Visit: http://www.abivax.com/en/
Connect with ABIVAX on partnering360®

Biotech Showcase™ 2016
Abzena
Abzena
(LSE:ABZA)
Cambridge, Massachusetts, United Kingdom
Abzena offers a suite of complementary services and technologies through its subsidiaries, PolyTherics, Antitope, PacificGMP and TCRS to enable the development of better bioph...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Abzena

Abzena is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 11:30 am. Room Powell.
Abzena
Track: D
City: Cambridge
State: Massachusetts
Country: United Kingdom
Ownership: Public
Ticker: ABZA
Stock exchange: LSE
Abzena offers a suite of complementary services and technologies through its subsidiaries, PolyTherics, Antitope, PacificGMP and TCRS to enable the development of better biopharmaceuticals which will have a greater chance of reaching the market. It's core areas include immunogenicity assessment, protein engineering, GMP manufacturing and antibody drug conjugates.

Visit: http://www.abzena.com
Connect with Abzena on partnering360®

Biotech Showcase™ 2016
Achelios Therapeutics
Achelios Therapeutics
Chapel Hill, North Carolina, United States
Achelios is a specialty pharmaceutical company whose core competency is the reformulation and topical delivery of non-steroidal anti-inflammatory (NSAIDS) molecules to treat p...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Achelios Therapeutics

Achelios Therapeutics is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 9:15 am. Room Hearst.
Achelios Therapeutics
Track: A
City: Chapel Hill
State: North Carolina
Country: United States
Ownership: Private
Achelios is a specialty pharmaceutical company whose core competency is the reformulation and topical delivery of non-steroidal anti-inflammatory (NSAIDS) molecules to treat pain and inflammation. Achelios recently completed phase 2a in its lead indication, Acute migraine. additional indications underdevelopment migraine prophylaxis TMJ osteoarthritis, sprain and strains, post-operative pain.

Visit: http://www.achelios.com
Connect with Achelios Therapeutics on partnering360®

Biotech Showcase™ 2016
Actinium Pharmaceuticals
Actinium Pharmaceuticals
(NYSE-M:ATNM)
New York, New York, United States
Actinium Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. A...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Actinium Pharmaceuticals

Actinium Pharmaceuticals is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 9:30 am. Room Market Street.
Actinium Pharmaceuticals
Track: F
City: New York
State: New York
Country: United States
Ownership: Public
Ticker: ATNM
Stock exchange: NYSE-M
Actinium Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies.

Visit: http://www.actiniumpharma.com
Connect with Actinium Pharmaceuticals on partnering360®

Biotech Showcase™ 2016
Acucela Inc.
Acucela Inc.
(TSE:4589)
Seattle, Washington, United States
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening opht...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Acucela Inc.

Acucela Inc. is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 3:30 pm. Room Powell.
Acucela Inc.
Track: D
City: Seattle
State: Washington
Country: United States
Ownership: Public
Ticker: 4589
Stock exchange: TSE
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide.

Visit: http://acucela.com
Connect with Acucela Inc. on partnering360®

Biotech Showcase™ 2016
Adgero Biopharmaceuticals
Pittstown, New Jersey, United States
Adgero is focused on the development of photodynamic therapy for the treatment of rare, unmet medical needs, specifically orphan cancer indications. Our lead product candidate...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Adgero Biopharmaceuticals

Adgero Biopharmaceuticals is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 8:00 am. Room Hearst.
Track: A
City: Pittstown
State: New Jersey
Country: United States
Ownership: Private
Adgero is focused on the development of photodynamic therapy for the treatment of rare, unmet medical needs, specifically orphan cancer indications. Our lead product candidate, the REM-001 has been tested in late stage clinical trials for the treatment of cutaneous metastatic breast cancer, or CMBC.
Connect with Adgero Biopharmaceuticals on partnering360®

Biotech Showcase™ 2016
Adherium Limited
Adherium Limited
(ASX:ADR)
Melbourne, Victoria, Australia
Adherium is a global leader in digital health technologies which address sub optimal medication use in chronic disease. The Company's Smartinhaler platform has demonstrated im...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Adherium Limited

Adherium Limited is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 9:00 am. Room Mission II.
Adherium Limited
Track: C
City: Melbourne
State: Victoria
Country: Australia
Ownership: Public
Ticker: ADR
Stock exchange: ASX
Adherium is a global leader in digital health technologies which address sub optimal medication use in chronic disease. The Company's Smartinhaler platform has demonstrated improvements in adherence of 59% (adults) and 180% (children) and significant improvements to quality of life in independent clinical studies.

Visit: http://www.adherium.com
Connect with Adherium Limited on partnering360®

Biotech Showcase™ 2016
Adjuvance Technologies Inc.
Adjuvance Technologies Inc.
New York, New York, United States
Adjuvance is a clinical-stage company focused on developing novel adjuvants in various vaccines. Our Phase 1 asset SAPONEX™(synthetic QS-21) demonstrated safety and adjuvant...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Adjuvance Technologies Inc.

Adjuvance Technologies Inc. is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 9:45 am. Room Hearst.
Adjuvance Technologies Inc.
Track: A
City: New York
State: New York
Country: United States
Ownership: Private
Adjuvance is a clinical-stage company focused on developing novel adjuvants in various vaccines. Our Phase 1 asset SAPONEX™(synthetic QS-21) demonstrated safety and adjuvanticity comparable to QS-21, which is in several vaccines. Our lead product TQL1055, is a novel adjuvant demonstrating improved safety and effectiveness over QS-21 in numerous preclinical models.

Visit: http://www.adjuvancetechnologies.com
Connect with Adjuvance Technologies Inc. on partnering360®

Biotech Showcase™ 2016
AdminMed
AdminMed
Sunnyvale, California, United States
AdminMed is a medical device company producing hollow metal microneedle array devices (“AdminPen”) allowing more effective and painless delivery of many immunotherapies, v...


Share this:Email this pageShare this on LinkedInShare this on Twitter

AdminMed

AdminMed is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 5:00 pm. Room Davidson.
AdminMed
Track: E
City: Sunnyvale
State: California
Country: United States
Ownership: Private
AdminMed is a medical device company producing hollow metal microneedle array devices (“AdminPen”) allowing more effective and painless delivery of many immunotherapies, vaccines, liquid medical drugs, cosmetics, and hair growth supplements uniformly into 1cm2 area of the skin. ADMINPEN has an annual worldwide addressable market of at least $16 billion.

Visit: http://www.adminmed.com/
Connect with AdminMed on partnering360®

Biotech Showcase™ 2016
Aegle Therapeutics Corp
Aegle Therapeutics Corp
Miami, Florida, United States
Aegle Therapeutics is a pre-IND stage biotechnology company focused on the development of microvesicles (isolated from stem cells) as therapy for the treatment of burns, wound...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Aegle Therapeutics Corp

Aegle Therapeutics Corp is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 4:30 pm. Room Davidson.
Aegle Therapeutics Corp
Track: E
City: Miami
State: Florida
Country: United States
Ownership: Private
Aegle Therapeutics is a pre-IND stage biotechnology company focused on the development of microvesicles (isolated from stem cells) as therapy for the treatment of burns, wounds, orthopedic injury and cardiovascular disease. The company anticipates filing its first two INDs in 2016 for the treatment of burns and chronic pressure ulcers.

Visit: http://www.aegletherapeutics.com
Connect with Aegle Therapeutics Corp on partnering360®

Biotech Showcase™ 2016
Akron Biotechnologies
Akron Biotechnologies
Boca Raton, Florida, United States
Akron has a strategic focus on enabling tools, technologies, and services for the regenerative medicine industry. As a global supplier, Akron manufactures and distributes comp...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Akron Biotechnologies

Akron Biotechnologies is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 10:15 am. Room Davidson.
Akron Biotechnologies
Track: E
City: Boca Raton
State: Florida
Country: United States
Ownership: Private
Akron has a strategic focus on enabling tools, technologies, and services for the regenerative medicine industry. As a global supplier, Akron manufactures and distributes components and raw materials for cell therapy discovery, development, and commercialization.

Visit: http://www.akronbiotech.com/index.cfm
Connect with Akron Biotechnologies on partnering360®

Biotech Showcase™ 2016
Alan Therapeutics
Alan Therapeutics
San Diego, California, United States
Alan Therapeutics, Inc. is a sublingual drug delivery technology company. Its leading anaphylaxis/allergy product is one year from end-of-phase II and two years from NDA filin...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Alan Therapeutics

Alan Therapeutics is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 8:15 am. Room Hearst.
Alan Therapeutics
Track: A
City: San Diego
State: California
Country: United States
Ownership: Private
Alan Therapeutics, Inc. is a sublingual drug delivery technology company. Its leading anaphylaxis/allergy product is one year from end-of-phase II and two years from NDA filing. The product has clear advantages over current marketed auto-injectors, such as EpiPen. The annual market size is expected to be over $2 billion.

Visit: http://www.alanlab.com/
Connect with Alan Therapeutics on partnering360®

Biotech Showcase™ 2016
Alpha Cancer Technologies Inc.
Alpha Cancer Technologies Inc.
Toronto, Ontario, Canada
Alpha Cancer Technologies (ACT) is a clinical stage company developing cancer therapies based on proprietary platform for targeted delivery of chemotherapy to majority of canc...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Alpha Cancer Technologies Inc.

Alpha Cancer Technologies Inc. is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 2:15 pm. Room Davidson.
Alpha Cancer Technologies Inc.
Track: E
City: Toronto
State: Ontario
Country: Canada
Ownership: Private
Alpha Cancer Technologies (ACT) is a clinical stage company developing cancer therapies based on proprietary platform for targeted delivery of chemotherapy to majority of cancers. The key advantages of the technology include significant reduction in systemic toxicity and improved efficacy. ACT also has Phase II asset for treating myasthenia gravis.

Visit: http://www.alpha-cancer.com
Connect with Alpha Cancer Technologies Inc. on partnering360®

Biotech Showcase™ 2016
Altimmune, Inc.
Altimmune, Inc.
Gaithersburg, Maryland, United States
A clinical stage immunotherapeutic company developing products that stimulate robust immune responses for the prevention and treatment of disease. We have three clinical stage...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Altimmune, Inc.

Altimmune, Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 4:45 pm. Room Hearst.
Altimmune, Inc.
Track: A
City: Gaithersburg
State: Maryland
Country: United States
Ownership: Private
A clinical stage immunotherapeutic company developing products that stimulate robust immune responses for the prevention and treatment of disease. We have three clinical stage product candidates based on our two proprietary platform technologies that have been shown to activate the immune system in distinctly different ways than traditional vaccines.

Visit: http://www.altimmune.com
Connect with Altimmune, Inc. on partnering360®

Biotech Showcase™ 2016
Alveonix
Alveonix
Rotkreuz/Zug, Switzerland
Alveonix is a pharmaceutical development company focusing on TRPM-8 targets. Dry eyes is the 1st indication with proof of concept (POC) in Humans. Alveonix is now prepared to ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Alveonix

Alveonix is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 3:15 pm. Room Hearst.
Alveonix
Track: A
City: Rotkreuz/Zug
Country: Switzerland
Ownership: Private
Alveonix is a pharmaceutical development company focusing on TRPM-8 targets. Dry eyes is the 1st indication with proof of concept (POC) in Humans. Alveonix is now prepared to initiate detailed drug development programs to create value from these findings. We are looking for a Seed/Series A investment of 2 MioUSD.
Connect with Alveonix on partnering360®

Biotech Showcase™ 2016
Amedica
Amedica
(NASDAQ:AMDA)
Salt Lake City, Utah, United States
Amedica Corporation (NASDAQ: AMDA) is a commercial stage biomaterial platform company focused on the development of silicon nitride ceramics. The Company’s spine products ar...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Amedica

Amedica is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 10:30 am. Room Mission II.
Amedica
Track: C
City: Salt Lake City
State: Utah
Country: United States
Ownership: Public
Ticker: AMDA
Stock exchange: NASDAQ
Amedica Corporation (NASDAQ: AMDA) is a commercial stage biomaterial platform company focused on the development of silicon nitride ceramics. The Company’s spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM partnerships.

Visit: http://www.amedica.com/
Connect with Amedica on partnering360®

Biotech Showcase™ 2016
AnaMar AB
AnaMar AB
Gothenburg, Sweden
AnaMar is a clinical stage company with proprietary highly specific antagonists for the peripheral serotonin 5-HT-2B receptor: in phase I/II as a novel non-steroidal topical t...


Share this:Email this pageShare this on LinkedInShare this on Twitter

AnaMar AB

AnaMar AB is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 2:30 pm. Room Hearst.
AnaMar AB
Track: A
City: Gothenburg
Country: Sweden
Ownership: Private
AnaMar is a clinical stage company with proprietary highly specific antagonists for the peripheral serotonin 5-HT-2B receptor: in phase I/II as a novel non-steroidal topical treatment for atopic dermatitis, and in preclinical development for fibrotic conditions of the liver (NASH), lung (IPF) and skin (Systemic Sclerosis).

Visit: http://www.anamar.com
Connect with AnaMar AB on partnering360®

Biotech Showcase™ 2016
Angiocrine Bioscience
Angiocrine Bioscience
San Diego, California, United States
Angiocrine Bioscience develops a new class of regenerative medicine consisting of genetically-modified tissue-specific endothelial cells (E-CEL™) capable of guiding appropri...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Angiocrine Bioscience

Angiocrine Bioscience is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 8:30 am. Room Hearst.
Angiocrine Bioscience
Track: A
City: San Diego
State: California
Country: United States
Ownership: Private
Angiocrine Bioscience develops a new class of regenerative medicine consisting of genetically-modified tissue-specific endothelial cells (E-CEL™) capable of guiding appropriate proliferation and differentiation of tissue-specific stem cells into healing/regeneration. Lead programs: lung (COPD), musculoskeletal (tendon repair), and liver diseases (cirrhosis). For partnership: E-CEL HUVEC enabling technology for gene therapy .

Visit: http://www.angiocrinebio.com
Connect with Angiocrine Bioscience on partnering360®

Biotech Showcase™ 2016
ANGLE plc
ANGLE plc
(LSE:AGL)
Guildford, Surrey, United Kingdom
ANGLE is commercializing its proprietary Parsortix system to harvest circulating tumor cells from cancer patient blood for a non-invasive liquid biopsy for precision medicine....


Share this:Email this pageShare this on LinkedInShare this on Twitter

ANGLE plc

ANGLE plc is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 2:30 pm. Room Market Street.
ANGLE plc
Track: F
City: Guildford, Surrey
Country: United Kingdom
Ownership: Public
Ticker: AGL
Stock exchange: LSE
ANGLE is commercializing its proprietary Parsortix system to harvest circulating tumor cells from cancer patient blood for a non-invasive liquid biopsy for precision medicine. Strong evidence has been published in ovarian, prostate, breast and lung cancers and ANGLE is in advanced development of its first clinical application in ovarian cancer.

Visit: http://www.angleplc.com
Connect with ANGLE plc on partnering360®

Biotech Showcase™ 2016
Anteo Diagnostics Limited
Anteo Diagnostics Limited
(ASX:ADO)
Eight Mile Plains, Queensland, Autralia
A global medical technology company, developing and commercialising products for sale into the lifesciences, IVD, POC, medical devices and bioseparations markets. Anteo owns a...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Anteo Diagnostics Limited

Anteo Diagnostics Limited is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 10:30 am. Room Mission I.
Anteo Diagnostics Limited
Track: B
City: Eight Mile Plains
State: Queensland
Country: Autralia
Ownership: Public
Ticker: ADO
Stock exchange: ASX
A global medical technology company, developing and commercialising products for sale into the lifesciences, IVD, POC, medical devices and bioseparations markets. Anteo owns a patented nanoglue technology, used as an addition to existing lab tests, consistently delivers test results faster, cheaper, with greater specificity or sensitivity than incumbent tests.

Visit: http://www.anteodx.com
Connect with Anteo Diagnostics Limited on partnering360®

Biotech Showcase™ 2016
Antisense Therapeutics Limited
Antisense Therapeutics Limited
(ASX:ANP)
Toorak, Victoria, Australia
Antisense Therapeutics Ltd is an Australian biotech company developing its advanced-stage pipeline of novel second-generation antisense drugs. Lead compounds are in Phase 2 cl...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Antisense Therapeutics Limited

Antisense Therapeutics Limited is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 4:00 pm. Room Mission I.
Antisense Therapeutics Limited
Track: B
City: Toorak
State: Victoria
Country: Australia
Ownership: Public
Ticker: ANP
Stock exchange: ASX
Antisense Therapeutics Ltd is an Australian biotech company developing its advanced-stage pipeline of novel second-generation antisense drugs. Lead compounds are in Phase 2 clinical development, acting on validated targets in acromegaly and multiple sclerosis. Leveraging technology partnership/exclusive worldwide licensing agreement with antisense world leader, Isis Pharmaceuticals.

Visit: http://www.antisense.com.au
Connect with Antisense Therapeutics Limited on partnering360®

Biotech Showcase™ 2016
Apexigen
Apexigen
San Carlos, California, United States
Apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative antibody-based drugs for the treatment of cancer with a focus on novel immuno-onco...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Apexigen

Apexigen is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 9:45 am. Room Davidson.
Apexigen
Track: E
City: San Carlos
State: California
Country: United States
Ownership: Private
Apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative antibody-based drugs for the treatment of cancer with a focus on novel immuno-oncology antibody therapeutics. Its lead candidate, APX005M, is currently in Phase 1 for the treatment of solid tumors. Two additional immuno-oncology programs are in preclinical development.

Visit: http://www.apexigen.com
Connect with Apexigen on partnering360®

Biotech Showcase™ 2016
ApolloDx
ApolloDx
Salt Lake City, Utah, United States
ApolloDx, LLC is a in vitro (IVD) mobile point-of-care (POC) diagnostic company which offers a new paradigm utilizing advanced technology and decentralized testing in conjunct...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ApolloDx

ApolloDx is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 8:30 am. Room Davidson.
ApolloDx
Track: E
City: Salt Lake City
State: Utah
Country: United States
Ownership: Private
ApolloDx, LLC is a in vitro (IVD) mobile point-of-care (POC) diagnostic company which offers a new paradigm utilizing advanced technology and decentralized testing in conjunction with backend connectivity to a centralized data repository. ApolloDx offers realtime laboratory quality results at the POC in ten minutes or less.

Visit: http://www.apollodx.com
Connect with ApolloDx on partnering360®

Biotech Showcase™ 2016
Aptuit Holdings LLC
Aptuit Holdings LLC
Greenwich, Connecticut, United States
Aptuit provides the most complete set of integrated early discovery to mid-Phase drug development services in the pharmaceutical industry including Drug Design & Discovery, AP...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Aptuit Holdings LLC

Aptuit Holdings LLC is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 9:30 am. Room Davidson.
Aptuit Holdings LLC
Track: E
City: Greenwich
State: Connecticut
Country: United States
Ownership: Private
Aptuit provides the most complete set of integrated early discovery to mid-Phase drug development services in the pharmaceutical industry including Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, Preclinical and IND enabling GLP/GMP programs. Fully integrated services are available from a single site in Verona, Italy.

Visit: http://www.aptuit.com
Connect with Aptuit Holdings LLC on partnering360®

Biotech Showcase™ 2016
Arch Therapeutics
Arch Therapeutics
(OTCQB:ARTH)
Framingham, Massachusetts, United States
Arch Therapeutics, Inc. is a biotechnology company developing novel hemostatic agents and sealants based on an innovative self-assembling peptide technology platform in order ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Arch Therapeutics

Arch Therapeutics is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 11:00 am. Room Mission I.
Arch Therapeutics
Track: B
City: Framingham
State: Massachusetts
Country: United States
Ownership: Public
Ticker: ARTH
Stock exchange: OTCQB
Arch Therapeutics, Inc. is a biotechnology company developing novel hemostatic agents and sealants based on an innovative self-assembling peptide technology platform in order to improve surgery and trauma care. Arch's first product candidate, the AC5 Surgical Hemostatic Device™, has recently received clinical trial clearance for Europe, the initial target market.

Visit: http://www.archtherapeutics.com
Connect with Arch Therapeutics on partnering360®

Biotech Showcase™ 2016
Arcturus Therapeutics
Arcturus Therapeutics
San Diego, California, United States
Arcturus Therapeutics is an industry leader in the application of RNA technologies for the treatment of disease and improved quality of life. The company’s aim is to develop...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Arcturus Therapeutics

Arcturus Therapeutics is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 8:15 am. Room Davidson.
Arcturus Therapeutics
Track: E
City: San Diego
State: California
Country: United States
Ownership: Private
Arcturus Therapeutics is an industry leader in the application of RNA technologies for the treatment of disease and improved quality of life. The company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. Backed by a management team with extensive

Visit: http://arcturusrx.com/
Connect with Arcturus Therapeutics on partnering360®

Biotech Showcase™ 2016
Aridis Pharmaceuticals
Aridis Pharmaceuticals
San Jose, California, United States
Aridis is a private biotech focusing on lung infections. We have a strong portfolio of novel anti-infective candidates and a human mAb discovery platform. Human monoclonal ant...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Aridis Pharmaceuticals

Aridis Pharmaceuticals is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 10:45 am. Room Hearst.
Aridis Pharmaceuticals
Track: A
City: San Jose
State: California
Country: United States
Ownership: Private
Aridis is a private biotech focusing on lung infections. We have a strong portfolio of novel anti-infective candidates and a human mAb discovery platform. Human monoclonal antibodies AR-101 and AR-301 are currently at Phase 2a clinical testing in acute pneumonia (HAP/VAP) patients, with another mAb candidate ready for Phase 2.

Visit: http://www.aridispharma.com
Connect with Aridis Pharmaceuticals on partnering360®

Biotech Showcase™ 2016
Armetheon, Inc.
Armetheon, Inc.
Milpitas, California, United States
Armetheon is a privately held, specialty pharmaceutical company developing and commercializing innovative medicines addressing major unmet needs in cardiovascular disease, ini...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Armetheon, Inc.

Armetheon, Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 10:45 am. Room Davidson.
Armetheon, Inc.
Track: E
City: Milpitas
State: California
Country: United States
Ownership: Private
Armetheon is a privately held, specialty pharmaceutical company developing and commercializing innovative medicines addressing major unmet needs in cardiovascular disease, initially in thrombosis. Armetheon's lead candidate, Tecarfarin, is being investigated for use as a Vitamin K Antagonist and is currently in Phase 3 development for prevention and management of thrombosis.

Visit: http://www.armetheon.com
Connect with Armetheon, Inc. on partnering360®

Biotech Showcase™ 2016
Asterias Biotherapeutics
Asterias Biotherapeutics
(NYSE-M:AST)
Fremont, California, United States
Asterias Biotherapeutics, Inc. is a leading biotechnology company in the regenerative medicine field. The Company’s proprietary platforms are based on its pluripotent stem c...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Asterias Biotherapeutics

Asterias Biotherapeutics is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 9:00 am. Room Mission I.
Asterias Biotherapeutics
Track: B
City: Fremont
State: California
Country: United States
Ownership: Public
Ticker: AST
Stock exchange: NYSE-M
Asterias Biotherapeutics, Inc. is a leading biotechnology company in the regenerative medicine field. The Company’s proprietary platforms are based on its pluripotent stem cell and dendritic cell immunotherapy technologies. Asterias is currently conducting a Phase 2 clinical trial in cervical spine injury and is planning a pivotal study in AML.

Visit: http://asteriasbiotherapeutics.com/
Connect with Asterias Biotherapeutics on partnering360®

Biotech Showcase™ 2016
Athersys, Inc.
Athersys, Inc.
(NASDAQ:ATHX)
Cleveland, Ohio, United States
Athersys is a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our prima...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Athersys, Inc.

Athersys, Inc. is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 3:30 pm. Room Market Street.
Athersys, Inc.
Track: F
City: Cleveland
State: Ohio
Country: United States
Ownership: Public
Ticker: ATHX
Stock exchange: NASDAQ
Athersys is a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our primary focus is the treatment of medical conditions where there is significant unmet clinical need, utilizing our regenerative medicine and other technologies.

Visit: http://www.athersys.com/
Connect with Athersys, Inc. on partnering360®

Biotech Showcase™ 2016
Aurora Biopharma
Cambridge, Massachusetts, United States
Aurora BioPharma, Inc. is a privately-held biopharmaceutical company discovering and commercializing cutting edge cancer immunotherapy drugs. Aurora's portfolio includes Chime...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Aurora Biopharma

Aurora Biopharma is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 9:15 am. Room Hearst.
Track: A
City: Cambridge
State: Massachusetts
Country: United States
Ownership: Private
Aurora BioPharma, Inc. is a privately-held biopharmaceutical company discovering and commercializing cutting edge cancer immunotherapy drugs. Aurora's portfolio includes Chimeric Antigen Receptor T-cell therapy (CAR T) in preclinical and clinical trials in liquid as well as solid tumor.

Visit: http://www.aurorabiopharma.net

Biotech Showcase™ 2016
Avectas
Avectas
Cambridge, Massachusetts, United States
Avectas has developed a unique vector-free delivery technology. We have demonstrated its utility with a focus on gene-editing. Leading edge efficiency and viability are achiev...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Avectas

Avectas is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 4:45 pm. Room Davidson.
Avectas
Track: E
City: Cambridge
State: Massachusetts
Country: United States
Ownership: Private
Avectas has developed a unique vector-free delivery technology. We have demonstrated its utility with a focus on gene-editing. Leading edge efficiency and viability are achieved without vector related limitations. Demonstrated in cells including immune and stem cells ex-vivo and in-vivo. Commercializing proof of concept science via value-creating partnerships.

Visit: http://www.avectas.com
Connect with Avectas on partnering360®

Biotech Showcase™ 2016
AVEO Oncology
AVEO Oncology
(NASDAQ:AVEO)
Cambrige, Massachusetts, United States
AVEO Oncology (AVEO) is a biopharmaceutical company committed to developing targeted therapies through biomarker-driven insights to provide improvements in patient outcomes wh...


Share this:Email this pageShare this on LinkedInShare this on Twitter

AVEO Oncology

AVEO Oncology is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 4:00 pm. Room Powell.
AVEO Oncology
Track: D
City: Cambrige
State: Massachusetts
Country: United States
Ownership: Public
Ticker: AVEO
Stock exchange: NASDAQ
AVEO Oncology (AVEO) is a biopharmaceutical company committed to developing targeted therapies through biomarker-driven insights to provide improvements in patient outcomes where significant unmet medical needs exist.

Visit: http://www.aveooncology.com/
Connect with AVEO Oncology on partnering360®

Biotech Showcase™ 2016
Avexxin AS
Avexxin AS
Trondheim, Norway
Avexxin AS is a clinical stage company focused on novel small molecule therapeutics for patients with chronic inflammatory conditions. Based on cPLA2 targeting, Avexxin provid...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Avexxin AS

Avexxin AS is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 10:00 am. Room Hearst.
Avexxin AS
Track: A
City: Trondheim
Country: Norway
Ownership: Private
Avexxin AS is a clinical stage company focused on novel small molecule therapeutics for patients with chronic inflammatory conditions. Based on cPLA2 targeting, Avexxin provides a unique anti-inflammatory platform. We have focused on psoriasis, RA, and glomerular nephritis in the initial stages. We are currently seeking investment.

Visit: http://www.avexxin.com
Connect with Avexxin AS on partnering360®

Biotech Showcase™ 2016
Axsome Therapeutics
Axsome Therapeutics
(NASDAQ:AXSM)
New York, New York, United States
Axsome is a Phase 3 stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system disorders. Our product candidate por...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Axsome Therapeutics

Axsome Therapeutics is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 10:00 am. Room Mission II.
Axsome Therapeutics
Track: C
City: New York
State: New York
Country: United States
Ownership: Public
Ticker: AXSM
Stock exchange: NASDAQ
Axsome is a Phase 3 stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system disorders. Our product candidate portfolio includes two late-stage candidates, AXS-02 and AXS-05, which we are developing for multiple indications where current treatment options are limited or inadequate.

Visit: http:////axsome.com/
Connect with Axsome Therapeutics on partnering360®

Biotech Showcase™ 2016
Aytu BioScience, Inc.
Aytu BioScience, Inc.
(OTCQB:AYTU)
Englewood, Colorado, United States
Aytu BioScience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. Aytu is currently marketing products in pro...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Aytu BioScience, Inc.

Aytu BioScience, Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 3:30 pm. Room Mission I.
Aytu BioScience, Inc.
Track: B
City: Englewood
State: Colorado
Country: United States
Ownership: Public
Ticker: AYTU
Stock exchange: OTCQB
Aytu BioScience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. Aytu is currently marketing products in prostate cancer (ProstaScint), UTIs (Primsol) and male infertility (MiOXSYS) and plans to expand into other urological indications for which there are significant medical needs.

Visit: http://www.aytubio.com
Connect with Aytu BioScience, Inc. on partnering360®

Biotech Showcase™ 2016
Azevan Pharmaceuticals
Azevan Pharmaceuticals
Bethlehem, Pennsylvania, United States
Azevan's first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of stress-related CNS disorders...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Azevan Pharmaceuticals

Azevan Pharmaceuticals is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 4:15 pm. Room Davidson.
Azevan Pharmaceuticals
Track: E
City: Bethlehem
State: Pennsylvania
Country: United States
Ownership: Private
Azevan's first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of stress-related CNS disorders. Three Phase II clinical trials are underway for treating: 1) Intermittant Explosive Disorder, 2) Irritability in Huntington Disease Patients, and 3) Post-traumatic Stress Disorder.

Visit: http://www.azevan.com
Connect with Azevan Pharmaceuticals on partnering360®

Biotech Showcase™ 2016
AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc.
Brooklyn, New York, United States
AzurRx BioPharma develops non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and micro biome-related infectious diseases. Our MS1819 li...


Share this:Email this pageShare this on LinkedInShare this on Twitter

AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc. is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 8:45 am. Room Davidson.
AzurRx BioPharma, Inc.
Track: E
City: Brooklyn
State: New York
Country: United States
Ownership: Private
AzurRx BioPharma develops non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and micro biome-related infectious diseases. Our MS1819 lipase is a yeast derived recombinant enzyme for treating exocrine pancreatic insufficiency (EPI). It is in phase 2 trials for patients with cystic fibrosis and chronic pancreatitis.

Visit: http://www.azurrx.com

Biotech Showcase™ 2016
Bantam Pharmaceutical
Bantam Pharmaceutical
New York, New York, United States
Bantam is a pre-clinical company focused on development of novel small molecule inhibitors of mRNA translation initiation for treating cancer. Bantam’s lead molecules target...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Bantam Pharmaceutical

Bantam Pharmaceutical is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 10:30 am. Room Hearst.
Bantam Pharmaceutical
Track: A
City: New York
State: New York
Country: United States
Ownership: Private
Bantam is a pre-clinical company focused on development of novel small molecule inhibitors of mRNA translation initiation for treating cancer. Bantam’s lead molecules target eIF4E which operates at the convergence point of multiple cancer signaling pathways and selectively regulates production of proteins that mediate critical functions required for cancer growth.
Connect with Bantam Pharmaceutical on partnering360®

Biotech Showcase™ 2016
bBHC
bBHC
Seoul, Korea, South
Seeking out-licensing, investment and collaboration using our pluripotent stem cell without side effects and its differentiated cells. Noteworthy features include mass product...


Share this:Email this pageShare this on LinkedInShare this on Twitter

bBHC

bBHC is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 2:45 pm. Room Hearst.
bBHC
Track: A
City: Seoul
Country: Korea, South
Ownership: Private
Seeking out-licensing, investment and collaboration using our pluripotent stem cell without side effects and its differentiated cells. Noteworthy features include mass production (i. up to 3x production efficacy ii. 2 weeks from MSC into pluripotent stem cell) and excellent outcome (in-vitro) especially with the neurocyte and pancreatic beta cell.

Visit: http://stcstri.com/
Connect with bBHC on partnering360®

Biotech Showcase™ 2016
BC Platforms
BC Platforms
Basel, Switzerland
BC Platforms is a leading innovator in the rapidly growing healthcare informatics and genomic data management markets. Our high-performing platform enables flexible data integ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BC Platforms

BC Platforms is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 8:15 am. Room Hearst.
BC Platforms
Track: A
City: Basel
Country: Switzerland
Ownership: Private
BC Platforms is a leading innovator in the rapidly growing healthcare informatics and genomic data management markets. Our high-performing platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. Our vision is to revolutionize drug development and clinical decision-making to bring personalized medicines to patients.

Visit: http://bcplatforms.com
Connect with BC Platforms on partnering360®

Biotech Showcase™ 2016
Bell Biosystems
Bell Biosystems
San Francisco, California, United States
Identified by the White House as a revolutionary platform technology in 2014, our technology enables insertion of complex functions into cells. Our Magnelle® cell tracking so...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Bell Biosystems

Bell Biosystems is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 11:15 am. Room Davidson.
Bell Biosystems
Track: E
City: San Francisco
State: California
Country: United States
Ownership: Private
Identified by the White House as a revolutionary platform technology in 2014, our technology enables insertion of complex functions into cells. Our Magnelle® cell tracking solution addresses key roadblocks in the rapidly growing $40B regenerative medicine market. With strong IP and market traction, we are seeking additional funds to accelerate.

Visit: http://www.bellbiosystems.com
Connect with Bell Biosystems on partnering360®

Biotech Showcase™ 2016
Benitec Biopharma
Benitec Biopharma
(NASDAQ:BNTC)
Sydney, New South Wales, Australia
Benitec Biopharma is a clinical-stage biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi. Benitec is develo...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Benitec Biopharma

Benitec Biopharma is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 2:30 pm. Room Mission I.
Benitec Biopharma
Track: B
City: Sydney
State: New South Wales
Country: Australia
Ownership: Public
Ticker: BNTC
Stock exchange: NASDAQ
Benitec Biopharma is a clinical-stage biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi. Benitec is developing therapeutics for hepatitis C and B, wet AMD, and OPMD. Benitec has also licensed ddRNAi to other biopharmaceutical companies for HIV/AIDS, Huntington's Disease, chronic neuropathic pain and retinitis pigmentosa.

Visit: http://www.benitec.com
Connect with Benitec Biopharma on partnering360®

Biotech Showcase™ 2016
BerGenBio
BerGenBio
Bergen, Norway
Clinical stage oncology biotech developing first-in-class drugs for aggressive, drug resistant and immune evasive cancers. Phase I / II trials on going in AML and NSCLC in Eur...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BerGenBio

BerGenBio is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 10:15 am. Room Hearst.
BerGenBio
Track: A
City: Bergen
Country: Norway
Ownership: Private
Clinical stage oncology biotech developing first-in-class drugs for aggressive, drug resistant and immune evasive cancers. Phase I / II trials on going in AML and NSCLC in Europe and USA. Pipeline of first-in-class EMT inhibitors.

Visit: http://www.bergenbio.com
Connect with BerGenBio on partnering360®

Biotech Showcase™ 2016
BeyondSpring
BeyondSpring
New York, New York, United States
BeyondSpring is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. Its lead asset, Plinabulin, is in a Phase III in lung can...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BeyondSpring

BeyondSpring is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 3:30 pm. Room Davidson.
BeyondSpring
Track: E
City: New York
State: New York
Country: United States
Ownership: Private
BeyondSpring is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. Its lead asset, Plinabulin, is in a Phase III in lung cancer (NSCLC) trial enrolling a total of 550 patients (75% China, 25% U.S.).

Visit: http://www.beyondspringpharma.com/
Connect with BeyondSpring on partnering360®

Biotech Showcase™ 2016
BIND Therapeutics
(NASDAQ:BIND)
Cambridge, Massachusetts, United States
Developing targeted nanoparticles called Accurins, for cancer and other diseases. Accurins are capable of exploiting potent biological pathways and delivering a range of paylo...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BIND Therapeutics

BIND Therapeutics is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 4:00 pm. Room Powell.
Track: D
City: Cambridge
State: Massachusetts
Country: United States
Ownership: Public
Ticker: BIND
Stock exchange: NASDAQ
Developing targeted nanoparticles called Accurins, for cancer and other diseases. Accurins are capable of exploiting potent biological pathways and delivering a range of payloads, including oligonucleotides. Lead candidate, BIND-014, is in mid-stage clinical development for lung cancer and multiple rare tumors. Strategic partners include AstraZeneca, Merck, Pfizer and Roche.

Visit: http://www.bindtherapeutics.com

Biotech Showcase™ 2016
Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc.
(NASDAQ:BPTH)
Bellaire, Texas, United States
BPTH is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 11:30 am. Room Mission I.
Bio-Path Holdings, Inc.
Track: B
City: Bellaire
State: Texas
Country: United States
Ownership: Public
Ticker: BPTH
Stock exchange: NASDAQ
BPTH is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Lead product candidate, BP1001 (Liposomal Grb2 antisense), is in Phase II study for blood cancers.

Visit: http://biopathholdings.com/
Connect with Bio-Path Holdings, Inc. on partnering360®

Biotech Showcase™ 2016
BioLife Solutions, Inc.
BioLife Solutions, Inc.
(NASDAQ:BLFS)
Bothell, Washington, United States
BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and smart shipping services improve the quality of delivery logistics f...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BioLife Solutions, Inc.

BioLife Solutions, Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 10:00 am. Room Mission I.
BioLife Solutions, Inc.
Track: B
City: Bothell
State: Washington
Country: United States
Ownership: Public
Ticker: BLFS
Stock exchange: NASDAQ
BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and smart shipping services improve the quality of delivery logistics for cells, tissues, and organs. The Company’s proprietary platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets.

Visit: http://www.biolifesolutions.com/
Connect with BioLife Solutions, Inc. on partnering360®

Biotech Showcase™ 2016
BioLineRx
BioLineRx
(NASDAQ:BLRX)
Modi'in, Israel
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, mainly from ac...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BioLineRx

BioLineRx is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 10:00 am. Room Market Street.
BioLineRx
Track: F
City: Modi'in
Country: Israel
Ownership: Public
Ticker: BLRX
Stock exchange: NASDAQ
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, mainly from academic institutions and biotech companies based in Israel, and primarily in oncology and immunology. BioLineRx and Novartis are partners in a strategic collaboration for the co-development of selected Israeli-sourced novel drug candidates.

Visit: http://www.biolinerx.com
Connect with BioLineRx on partnering360®

Biotech Showcase™ 2016
BiologicsMD
BiologicsMD
Fayetteville, Arkansas, United States
BiologicsMD is developing therapeutics and therapeutic-device combinations for the treatment of bone and hair-loss disorders. The core technology relies on targeting physiolog...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BiologicsMD

BiologicsMD is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 11:45 am. Room Davidson.
BiologicsMD
Track: E
City: Fayetteville
State: Arkansas
Country: United States
Ownership: Private
BiologicsMD is developing therapeutics and therapeutic-device combinations for the treatment of bone and hair-loss disorders. The core technology relies on targeting physiologically active agents to Type I collagen, found in skin and bone. BiologicsMD’s targeted approach minimizes off-target effects and increases the time of exposure at the sites of function.

Visit: http://www.biologicsmd.com
Connect with BiologicsMD on partnering360®

Biotech Showcase™ 2016
BioMarker Strategies, LLC
BioMarker Strategies, LLC
Rockville, Maryland, United States
BioMarker Strategies has developed the proprietary and recently patented SnapPath® Cancer Diagnostics System for predictive tests to guide targeted drug development and treat...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BioMarker Strategies, LLC

BioMarker Strategies, LLC is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 8:00 am. Room Hearst.
BioMarker Strategies, LLC
Track: A
City: Rockville
State: Maryland
Country: United States
Ownership: Private
BioMarker Strategies has developed the proprietary and recently patented SnapPath® Cancer Diagnostics System for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. Our mission is to make personalized medicine more of a reality for these patients.

Visit: http://www.biomarkerstrategies.com
Connect with BioMarker Strategies, LLC on partnering360®

Biotech Showcase™ 2016
Biomecite Diagnostics, LLC
Biomecite Diagnostics, LLC
Glen Burnie, Maryland, United States
Biomecite Diagnostics is a development-stage medical diagnostics company commercializing an Inflammatory Bowel Disease (IBD) diagnostic tool based on a microbiome signature te...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Biomecite Diagnostics, LLC

Biomecite Diagnostics, LLC is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 4:30 pm. Room Hearst.
Biomecite Diagnostics, LLC
Track: A
City: Glen Burnie
State: Maryland
Country: United States
Ownership: Private
Biomecite Diagnostics is a development-stage medical diagnostics company commercializing an Inflammatory Bowel Disease (IBD) diagnostic tool based on a microbiome signature technology. The technology relies on the analysis of signature genetic sequences obtained directly from patient stool samples and will provide physicians accurate diagnostic information within days.

Visit: http://www.biomecite.com
Connect with Biomecite Diagnostics, LLC on partnering360®

Biotech Showcase™ 2016
Bionik Laboratories Corp.
Bionik Laboratories Corp.
(OTCQX:BNKL)
Toronto, Ontario, Canada
Bionik is a pioneering medical device/robotics company building a portfolio of technologies and solutions for individuals with neurological disorders. Bionik’s primary produ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Bionik Laboratories Corp.

Bionik Laboratories Corp. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 9:30 am. Room Mission II.
Bionik Laboratories Corp.
Track: C
City: Toronto
State: Ontario
Country: Canada
Ownership: Public
Ticker: BNKL
Stock exchange: OTCQX
Bionik is a pioneering medical device/robotics company building a portfolio of technologies and solutions for individuals with neurological disorders. Bionik’s primary product, ARKE™, a lower-body exoskeleton allowing paraplegics and other wheelchair users the ability to rehabilitate through walking and other motion, is entering clinical testing with data expected in 2016.

Visit: http://www.bioniklabs.com/
Connect with Bionik Laboratories Corp. on partnering360®

Biotech Showcase™ 2016
Bionomics
Bionomics
(ASX:BNO)
Thebarton, South Australia, Australia
Bionomics is a global, clinical-stage biopharmaceutical company, leveraging our proprietary platform technologies to discover and develop a deep pipeline of best in class, nov...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Bionomics

Bionomics is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 10:00 am. Room Mission I.
Bionomics
Track: B
City: Thebarton
State: South Australia
Country: Australia
Ownership: Public
Ticker: BNO
Stock exchange: ASX
Bionomics is a global, clinical-stage biopharmaceutical company, leveraging our proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of CNS disorders and on the treatment of cancer. Based in Australia, with operations in the US and Europe.

Visit: http://www.bionomics.com.au
Connect with Bionomics on partnering360®

Biotech Showcase™ 2016
Biopact
Biopact
Cambridge, Massachusetts, United States
BioPact is a medical nano-technology development company based in Cambridge, MA. BioPact’s Medical Grade Molecular Rebar (MGMR™), a unique composition of matter derived fr...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Biopact

Biopact is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 10:00 am. Room Davidson.
Biopact
Track: E
City: Cambridge
State: Massachusetts
Country: United States
Ownership: Private
BioPact is a medical nano-technology development company based in Cambridge, MA. BioPact’s Medical Grade Molecular Rebar (MGMR™), a unique composition of matter derived from carbon nanotubes, in development for use in drug delivery, orthotics, regenerative medicine, devices, diagnostics, bio-sensors, material optimization and other medical applications addressing substantial unmet needs.

Visit: http://www.bio-pact.com
Connect with Biopact on partnering360®

Biotech Showcase™ 2016
Biophytis
(EURONEXT:ALBPS)
Romainville, France
Biophytis is a public company listed on Euronext (ALBPS) focused on treating age-related diseases. Its lead products are currently entering phase 2b for dry AMD (MACULIA BIO20...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Biophytis

Biophytis is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 3:00 pm. Room Mission II.
Track: C
City: Romainville
Country: France
Ownership: Public
Ticker: ALBPS
Stock exchange: EURONEXT
Biophytis is a public company listed on Euronext (ALBPS) focused on treating age-related diseases. Its lead products are currently entering phase 2b for dry AMD (MACULIA BIO201) and sarcopenic obesity (SARCOB BIO101).

Visit: http://www.biophytis.com
Connect with Biophytis on partnering360®

Biotech Showcase™ 2016
Biosceptre
Biosceptre
North Ryde, New South Wales, Australia
Biosceptre is a clinical stage company focused on treating cancer. Its IP portfolio includes a novel oncology target -nfPX7 -and there are currently 3 products for the treatme...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Biosceptre

Biosceptre is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 9:00 am. Room Hearst.
Biosceptre
Track: A
City: North Ryde
State: New South Wales
Country: Australia
Ownership: Private
Biosceptre is a clinical stage company focused on treating cancer. Its IP portfolio includes a novel oncology target -nfPX7 -and there are currently 3 products for the treatment of cancer in Phase 1 or post Phase 1. It also has two pre-clinical compound programs underway.

Visit: http://www.biosceptre.com
Connect with Biosceptre on partnering360®

Biotech Showcase™ 2016
Biosig Technologies
Biosig Technologies
(OTCQB:BSGM)
Los Angeles, California, United States
Biosig Tecnologies is a medical device company developing a proprietary technology platform designed to improve the rapidly growing $3 billion electrophysiology (EP) marketpla...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Biosig Technologies

Biosig Technologies is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 11:30 am. Room Mission I.
Biosig Technologies
Track: B
City: Los Angeles
State: California
Country: United States
Ownership: Public
Ticker: BSGM
Stock exchange: OTCQB
Biosig Tecnologies is a medical device company developing a proprietary technology platform designed to improve the rapidly growing $3 billion electrophysiology (EP) marketplace. Their "PURE EP" System is designed to improve the clarity of clinical signals available for EP studies and cardiac catheter ablation, helping to better treat cardiac arrhythmias.

Visit: http://biosigtech.com/
Connect with Biosig Technologies on partnering360®

Biotech Showcase™ 2016
Biosortia Pharmaceuticals
Biosortia Pharmaceuticals
Dublin, Ohio, United States
Biosortia Pharmaceuticals leverages Nature for the discovery of first-in-class small molecules as potential solutions to high priority unmet needs that will positively impact ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Biosortia Pharmaceuticals

Biosortia Pharmaceuticals is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 3:45 pm. Room Davidson.
Biosortia Pharmaceuticals
Track: E
City: Dublin
State: Ohio
Country: United States
Ownership: Private
Biosortia Pharmaceuticals leverages Nature for the discovery of first-in-class small molecules as potential solutions to high priority unmet needs that will positively impact human health. Biosortia's primary compound pipeline priorities are: anti-cancer (various), autoimmune (IL-17), cardiovascular (PCSK9), inflammation, CNS-anticonvulsants, and unmet/orphan. Contact- CEO/Founder- Ross Youngs

Visit: http://www.biosortia.com
Connect with Biosortia Pharmaceuticals on partnering360®

Biotech Showcase™ 2016
Biotron Limited
Biotron Limited
(ASX:BIT)
Sydney, New South Wales, Asutralia
Biotron is a mid-stage drug development company focused on small molecule antiviral drugs. BIT225 is a first-in-class drug that has shown good clinical efficacy against HCV an...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Biotron Limited

Biotron Limited is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 5:00 pm. Room Powell.
Biotron Limited
Track: D
City: Sydney
State: New South Wales
Country: Asutralia
Ownership: Public
Ticker: BIT
Stock exchange: ASX
Biotron is a mid-stage drug development company focused on small molecule antiviral drugs. BIT225 is a first-in-class drug that has shown good clinical efficacy against HCV and HIV. The company also has promising earlier stage programs for other viruses including HBV and Dengue virus.

Visit: http://www.biotron.com.au
Connect with Biotron Limited on partnering360®

Biotech Showcase™ 2016
Blend Therapeutics
Blend Therapeutics
Watertown, Massachusetts, United States
Blend’s Pentarins are targeted miniature drug conjugates that remain miniature by design for deep tumor penetration to drive efficacy and overcome limitations of ADCs. The f...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Blend Therapeutics

Blend Therapeutics is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 9:30 am. Room Davidson.
Blend Therapeutics
Track: E
City: Watertown
State: Massachusetts
Country: United States
Ownership: Private
Blend’s Pentarins are targeted miniature drug conjugates that remain miniature by design for deep tumor penetration to drive efficacy and overcome limitations of ADCs. The first of a pipeline of Pentarins, PEN-221, targeting the somatostatin-receptor in neuroendrocrine cancers including SCLC and carcinoids is poised to enter the clinic mid-2016

Visit: http://www.blendtx.com
Connect with Blend Therapeutics on partnering360®

Biotech Showcase™ 2016
Bovie Medical Corporation
Bovie Medical Corporation
(NYSE-M:BVX)
Purchase, New York, United States
Bovie Medical manufactures medical devices and supplies and is the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation that provi...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Bovie Medical Corporation

Bovie Medical Corporation is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 2:30 pm. Room Mission II.
Bovie Medical Corporation
Track: C
City: Purchase
State: New York
Country: United States
Ownership: Public
Ticker: BVX
Stock exchange: NYSE-M
Bovie Medical manufactures medical devices and supplies and is the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation that provides superior precision, patient safety and minimal invasiveness. Bovie also manufactures several electrosurgical products, marketed through private labels and its own brands to distributors worldwide.

Visit: http://www.boviemedical.com/
Connect with Bovie Medical Corporation on partnering360®

Biotech Showcase™ 2016
C4X Discovery Holdings plc
C4X Discovery Holdings plc
(C4XD:LSE)
Manchester, United Kingdom
A drug discovery company that uniquely measures the dynamic 3D shapes of bioactive ligands that provide blueprints for small molecule drug design. C4XD has produced a high val...


Share this:Email this pageShare this on LinkedInShare this on Twitter

C4X Discovery Holdings plc

C4X Discovery Holdings plc is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 10:30 am. Room Market Street.
C4X Discovery Holdings plc
Track: F
City: Manchester
Country: United Kingdom
Ownership: Public
Ticker: LSE
Stock exchange: C4XD
A drug discovery company that uniquely measures the dynamic 3D shapes of bioactive ligands that provide blueprints for small molecule drug design. C4XD has produced a high value drug discovery pipeline containing potential therapies for Inflammatory diseases, Diabetes and Addictive disorders. Collaborative partners include AstraZeneca, Evotec, Takeda and the SGC.

Visit: http://www.c4xdiscovery.com
Connect with C4X Discovery Holdings plc on partnering360®

Biotech Showcase™ 2016
Califia Bio, Inc.
Califia Bio, Inc.
San Diego, California, United States
Califia Bio is a research company that collaborates with world class academic groups to bring new discoveries to the clinic. Our expertise is in medicinal chemistry, lead disc...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Califia Bio, Inc.

Califia Bio, Inc. is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 9:45 am. Room Davidson.
Califia Bio, Inc.
Track: E
City: San Diego
State: California
Country: United States
Ownership: Private
Califia Bio is a research company that collaborates with world class academic groups to bring new discoveries to the clinic. Our expertise is in medicinal chemistry, lead discovery, optimization and preclinical development. We are seeking partners to help us commercialize compounds for the treatment of PD, MS and glaucoma.

Visit: http://www.califiabio.com
Connect with Califia Bio, Inc. on partnering360®

Biotech Showcase™ 2016
Cambridge Medical Robotics
Cambridge Medical Robotics
Cambridge, United Kingdom
Cambridge Medical Robotics (CMR) is developing the next-generation robotic surgical system designed for minimal access or “keyhole” surgery. CMR is uniquely positioned to ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cambridge Medical Robotics

Cambridge Medical Robotics is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 8:30 am. Room Davidson.
Cambridge Medical Robotics
Track: E
City: Cambridge
Country: United Kingdom
Ownership: Private
Cambridge Medical Robotics (CMR) is developing the next-generation robotic surgical system designed for minimal access or “keyhole” surgery. CMR is uniquely positioned to disrupt the economics within the surgical robotics market, and the Company believes it will be first to market with the world’s only truly universal surgical robotic system.

Visit: http://www.cmedrobotics.com
Connect with Cambridge Medical Robotics on partnering360®

Biotech Showcase™ 2016
Can-Fite BioPharma
Can-Fite BioPharma
(NYSE-M:CANF)
Petach-Tikva, Israel
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) develops small molecule drugs, targeting the A3 adenosine receptor, for the treatment of cancer, inflammatory diseases and sexual dysf...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Can-Fite BioPharma

Can-Fite BioPharma is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 11:00 am. Room Mission I.
Can-Fite BioPharma
Track: B
City: Petach-Tikva
Country: Israel
Ownership: Public
Ticker: CANF
Stock exchange: NYSE-M
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) develops small molecule drugs, targeting the A3 adenosine receptor, for the treatment of cancer, inflammatory diseases and sexual dysfunction. CF101 is currently preparing to enter Phase III in Rheumatoid Arthritis and Psoriasis; CF102 is in Phase II studies for advanced Liver Cancer and has

Visit: http://www.canfite.com
Connect with Can-Fite BioPharma on partnering360®

Biotech Showcase™ 2016
CanBas
CanBas
(4575:TSE)
Shizuoka, Japan
CanBas's CBP501 completed two global Phase II studies. It showed promising signs in platinum resistant and refractory ovarian cancer and malignant pleural mesothelioma patient...


Share this:Email this pageShare this on LinkedInShare this on Twitter

CanBas

CanBas is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 5:00 pm. Room Powell.
CanBas
Track: D
City: Shizuoka
Country: Japan
Ownership: Public
Ticker: TSE
Stock exchange: 4575
CanBas's CBP501 completed two global Phase II studies. It showed promising signs in platinum resistant and refractory ovarian cancer and malignant pleural mesothelioma patients. Phase II in NSCLC led to the identification of the way to enrich responsive population and of the additional mechanism of action.

Visit: http://www.canbas.co.jp/

Biotech Showcase™ 2016
Canbex Therapeutics
Canbex Therapeutics
London, United Kingdom
Canbex is developing a validated platform of novel small molecule compounds that selectively regulate excitability in neuronal and endothelial cells via BKCa, with application...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Canbex Therapeutics

Canbex Therapeutics is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 2:15 pm. Room Hearst.
Canbex Therapeutics
Track: A
City: London
Country: United Kingdom
Ownership: Private
Canbex is developing a validated platform of novel small molecule compounds that selectively regulate excitability in neuronal and endothelial cells via BKCa, with applications in movement disorders, glaucoma, epilepsy, pain and others including the orphan paediatric disorder Fragile X Syndrome. Its lead compound is currently undergoing Phase II testing.

Visit: http://www.canbex.co.uk/
Connect with Canbex Therapeutics on partnering360®

Biotech Showcase™ 2016
Cancure Limited
Cancure Limited
Broadbeach, Queensland, Australia
Company has three oncology development programs, two in immuno-oncology and one a novel targeted therapy. Lead product CNC118 is a melanoma therapeutic vaccine, which has been...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cancure Limited

Cancure Limited is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 1:45 pm. Room Hearst.
Cancure Limited
Track: A
City: Broadbeach
State: Queensland
Country: Australia
Ownership: Private
Company has three oncology development programs, two in immuno-oncology and one a novel targeted therapy. Lead product CNC118 is a melanoma therapeutic vaccine, which has been used to treat 10 patients in a pilot Phase I study. Company is seeking to raise ~$12M to take three products to human POC.

Visit: http://www.cancure.com
Connect with Cancure Limited on partnering360®

Biotech Showcase™ 2016
Cantargia AB
Cantargia AB
(NASDAQ:CANTA)
Lund, Sweden
Cantargia is developing an antibody, CAN04, against the IL1RAP target molecule for cancer treatment. It has the potential to be used for treatment of several forms of cancer. ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cantargia AB

Cantargia AB is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 11:00 am. Room Powell.
Cantargia AB
Track: D
City: Lund
Country: Sweden
Ownership: Public
Ticker: CANTA
Stock exchange: NASDAQ
Cantargia is developing an antibody, CAN04, against the IL1RAP target molecule for cancer treatment. It has the potential to be used for treatment of several forms of cancer. Initial development activities is focused on non-small cell lung cancer (NSCLC) and pancreatic cancer and plan to start phase I trials 2016.

Visit: http://www.cantargia.com
Connect with Cantargia AB on partnering360®

Biotech Showcase™ 2016
Capricor Therapeutics
Capricor Therapeutics
(NASDAQ:CAPR)
Beverly Hills, California, United States
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the development of first-in-class therapeutics targeting post myocardial infarc...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Capricor Therapeutics

Capricor Therapeutics is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 4:00 pm. Room Mission I.
Capricor Therapeutics
Track: B
City: Beverly Hills
State: California
Country: United States
Ownership: Public
Ticker: CAPR
Stock exchange: NASDAQ
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the development of first-in-class therapeutics targeting post myocardial infarction, heart failure and Duchenne Muscular Dystrophy. The Company’s product candidates under investigation: CAP-1002, a cardiac cell therapy, Cenderitide, a natriuretic peptide and exosomes which are currently in pre-clinical development.

Visit: http://www.capricor.com
Connect with Capricor Therapeutics on partnering360®

Biotech Showcase™ 2016
Ceapro, Inc.
Ceapro, Inc.
(TSX-V:CZO)
Edmonton, Alberta, Canada
“Green”, revenue generating, growth-stage biotechnology company focused on identification, isolation, extraction, purification, development and commercialization of natura...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Ceapro, Inc.

Ceapro, Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 3:30 pm. Room Mission II.
Ceapro, Inc.
Track: C
City: Edmonton
State: Alberta
Country: Canada
Ownership: Public
Ticker: CZO
Stock exchange: TSX-V
“Green”, revenue generating, growth-stage biotechnology company focused on identification, isolation, extraction, purification, development and commercialization of natural, functionally active ingredients and extracts from oats, and other renewable botanical sources for healthcare and cosmetic industries through the use of proprietary Pressurized Gas eXpanded Liquid (PGX) technology and sustainable resources.

Visit: http://www.ceapro.com
Connect with Ceapro, Inc. on partnering360®

Biotech Showcase™ 2016
Celator Pharmaceuticals, Inc
(NASDAQ:CPXX)
Ewing, New Jersey, United States
Celator Pharmaceuticals, with locations in Ewing, N.J., and Vancouver, B.C., is a biopharmaceutical company that is transforming the science of combination therapy, and develo...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Celator Pharmaceuticals, Inc

Celator Pharmaceuticals, Inc is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 11:00 am. Room Mission II.
Track: C
City: Ewing
State: New Jersey
Country: United States
Ownership: Public
Ticker: CPXX
Stock exchange: NASDAQ
Celator Pharmaceuticals, with locations in Ewing, N.J., and Vancouver, B.C., is a biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator’s lead product, VYXEOS™ (formerly CPX-351) is completing pivotal Phase 3 trial for the treatment of acute myeloid leukemia.

Visit: http://www.celatorpharma.com/
Connect with Celator Pharmaceuticals, Inc on partnering360®

Biotech Showcase™ 2016
Cellceutix Corporation
Cellceutix Corporation
(NASDAQ:CTIX)
Beverly, Massachusetts, United States
Cellceutix is a publicly traded company, symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology (p53) (enterin...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cellceutix Corporation

Cellceutix Corporation is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 3:00 pm. Room Powell.
Cellceutix Corporation
Track: D
City: Beverly
State: Massachusetts
Country: United States
Ownership: Public
Ticker: CTIX
Stock exchange: NASDAQ
Cellceutix is a publicly traded company, symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology (p53) (entering Phase 2), psoriasis (completing Phase 2), ABSSSI (entering Phase 3), oral mucositis (Phase2). Cellceutix is now engaged in advancing its extensive library of compounds and seeking strategic partnerships.

Visit: http://www.cellceutix.com
Connect with Cellceutix Corporation on partnering360®

Biotech Showcase™ 2016
Cellectar Biosciences
Cellectar Biosciences
(NASDAQ:CLRB)
Madison, Wisconson, United States
Cellectar is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer s...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cellectar Biosciences

Cellectar Biosciences is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 5:00 pm. Room Mission I.
Cellectar Biosciences
Track: B
City: Madison
State: Wisconson
Country: United States
Ownership: Public
Ticker: CLRB
Stock exchange: NASDAQ
Cellectar is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs.

Visit: http://cellectarbiosciences.com/
Connect with Cellectar Biosciences on partnering360®

Biotech Showcase™ 2016
Cellular Biomedicine Group
Cellular Biomedicine Group
(NASDAQ:CBMG)
Cupertino, California, United States
CBMG develops cell therapies for treating cancerous and degenerative diseases. The Company’s CAR-T immuno-oncology and stem cell programs are researched and developed by lea...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cellular Biomedicine Group

Cellular Biomedicine Group is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 10:00 am. Room Mission II.
Cellular Biomedicine Group
Track: C
City: Cupertino
State: California
Country: United States
Ownership: Public
Ticker: CBMG
Stock exchange: NASDAQ
CBMG develops cell therapies for treating cancerous and degenerative diseases. The Company’s CAR-T immuno-oncology and stem cell programs are researched and developed by leading multi-national scientists targeting China’s large addressable market. CBMG’s China GMP facilities, consisting of nine independent cell production lines, are designed and managed according to U.S. standards.

Visit: http://www.cellbiomedgroup.com/
Connect with Cellular Biomedicine Group on partnering360®

Biotech Showcase™ 2016
Celsion
(NASDAQ:CLSN)
Lawrenceville, New Jersey, United States
Celsion Corporation is a fully integrated, clinical stage oncology company focused on the development of a portfolio of innovative cancer treatments, including directed chemot...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Celsion

Celsion is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 9:00 am. Room Mission I.
Track: B
City: Lawrenceville
State: New Jersey
Country: United States
Ownership: Public
Ticker: CLSN
Stock exchange: NASDAQ
Celsion Corporation is a fully integrated, clinical stage oncology company focused on the development of a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies for the treatment of cancer and other difficult-to-treat diseases.

Visit: http://www.celsion.com
Connect with Celsion on partnering360®

Biotech Showcase™ 2016
Cenna Biosciences Inc.
Cenna Biosciences Inc.
La Jolla, California, United States
Cenna Biosciences is a biopharmaceutical company dedicated to the discovery and development of novel drugs to prevent and treat Alzheimer’s disease (AD). Its novel technolog...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cenna Biosciences Inc.

Cenna Biosciences Inc. is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 10:45 am. Room Davidson.
Cenna Biosciences Inc.
Track: E
City: La Jolla
State: California
Country: United States
Ownership: Private
Cenna Biosciences is a biopharmaceutical company dedicated to the discovery and development of novel drugs to prevent and treat Alzheimer’s disease (AD). Its novel technology has produced peptide drug candidates which can reduce Aß in vitro and in a transgenic mouse model of AD and are currently in preclinical development.

Visit: http://www.cennabiosciences.com
Connect with Cenna Biosciences Inc. on partnering360®

Biotech Showcase™ 2016
Cerecor Inc.
Cerecor Inc.
(NASDAQ:CERC)
Baltimore, Maryland, United States
Cerecor is a clinical-stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cerecor Inc.

Cerecor Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 11:30 am. Room Mission II.
Cerecor Inc.
Track: C
City: Baltimore
State: Maryland
Country: United States
Ownership: Public
Ticker: CERC
Stock exchange: NASDAQ
Cerecor is a clinical-stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders. We currently have three product candidates; two are in Phase 2, one is in preclinical development

Visit: http://www.cerecor.com
Connect with Cerecor Inc. on partnering360®

Biotech Showcase™ 2016
Cesca Therapeutics Inc.
Cesca Therapeutics Inc.
(NASDAQ:KOOL)
Rancho Cordova, California, United States
Cesca Therapeutics Inc. is a clinical stage company engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative m...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cesca Therapeutics Inc.

Cesca Therapeutics Inc. is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 11:30 am. Room Powell.
Cesca Therapeutics Inc.
Track: D
City: Rancho Cordova
State: California
Country: United States
Ownership: Public
Ticker: KOOL
Stock exchange: NASDAQ
Cesca Therapeutics Inc. is a clinical stage company engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. We are a leader in developing and manufacturing automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.

Visit: http://www.cescatherapeutics.com
Connect with Cesca Therapeutics Inc. on partnering360®

Biotech Showcase™ 2016
Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc.
(NASDAQ:CEMI)
Medford, New York, United States
Chembio is a leader in the development and commercialization of rapid diagnostic tests in the growing $8.0 billion point-of-care (POC) testing market. In addition to our brand...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Chembio Diagnostics, Inc.

Chembio Diagnostics, Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 9:30 am. Room Powell.
Chembio Diagnostics, Inc.
Track: D
City: Medford
State: New York
Country: United States
Ownership: Public
Ticker: CEMI
Stock exchange: NASDAQ
Chembio is a leader in the development and commercialization of rapid diagnostic tests in the growing $8.0 billion point-of-care (POC) testing market. In addition to our branded and proprietary HIV tests, which are sold in the U.S. and internationally, the company is developing POC diagnostic tests for multiple fever diseases.

Visit: http://www.chembio.com
Connect with Chembio Diagnostics, Inc. on partnering360®

Biotech Showcase™ 2016
Chronos Therapeutics
Chronos Therapeutics
Oxford, United Kingdom
Chronos is a clinical-stage Biotech company. Chronos researches behavioural and degenerative diseases of the nervous system using a proprietary phenotypic screen, Chronoscreen...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Chronos Therapeutics

Chronos Therapeutics is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 2:30 pm. Room Hearst.
Chronos Therapeutics
Track: A
City: Oxford
Country: United Kingdom
Ownership: Private
Chronos is a clinical-stage Biotech company. Chronos researches behavioural and degenerative diseases of the nervous system using a proprietary phenotypic screen, ChronoscreenTM. The company has active, late pre-clinical programmes in ALS and obesity and an acquisition programme for complementary molecules. Major investors are Oxford University, Vulpes and Odey Hedge funds

Visit: http://www.chronostherapeutics.com
Connect with Chronos Therapeutics on partnering360®

Biotech Showcase™ 2016
Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc.
(OTCQB:CTXR)
Maynard, Massachusetts, United States
Citius Pharmaceuticals (OTCQB: CTXR), a specialty pharmaceutical company commercializing new and expanded indications for previously approved pharmaceutical products. Suprenza...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 2:00 pm. Room Powell.
Citius Pharmaceuticals, Inc.
Track: D
City: Maynard
State: Massachusetts
Country: United States
Ownership: Public
Ticker: CTXR
Stock exchange: OTCQB
Citius Pharmaceuticals (OTCQB: CTXR), a specialty pharmaceutical company commercializing new and expanded indications for previously approved pharmaceutical products. Suprenza™, Citius’ first FDA-approved product, is a novel formulation of a leading obesity drug. Citius is also advancing a product candidate entering Phase 2a for the treatment of hemorrhoids, a gastrointestinal condition.

Visit: http://www.citiuspharma.com/
Connect with Citius Pharmaceuticals, Inc. on partnering360®

Biotech Showcase™ 2016
Cognition Therapeutics
Cognition Therapeutics
Pittsburgh, Pennsylvania, United States
Cognition Therapeutics Inc. (CogRx) is a clinical-stage small molecule CNS therapeutics company. Our first-in-class, orally-bioavailable Alzheimer's therapeutic is designed to...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cognition Therapeutics

Cognition Therapeutics is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 11:15 am. Room Davidson.
Cognition Therapeutics
Track: E
City: Pittsburgh
State: Pennsylvania
Country: United States
Ownership: Private
Cognition Therapeutics Inc. (CogRx) is a clinical-stage small molecule CNS therapeutics company. Our first-in-class, orally-bioavailable Alzheimer's therapeutic is designed to halt disease progression and improve symptoms in Alzheimer’s disease through a novel synaptic protection mechanism (Abeta oligomer receptor antagonism). We have a second preclinical program in Parkinson's disease.

Visit: http://www.cogrx.com
Connect with Cognition Therapeutics on partnering360®

Biotech Showcase™ 2016
Complexa
Complexa
Radnor, Pennsylvania, United States
Complexa is a clinical stage fibrosis and inflammation biopharmaceutical company targeting orphan diseases for its endogenous nitro-fatty acid technology. Complexa plans to en...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Complexa

Complexa is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 2:00 pm. Room Davidson.
Complexa
Track: E
City: Radnor
State: Pennsylvania
Country: United States
Ownership: Private
Complexa is a clinical stage fibrosis and inflammation biopharmaceutical company targeting orphan diseases for its endogenous nitro-fatty acid technology. Complexa plans to enter two Phase 2 trials in FSGS (orphan renal) and PAH in early/mid 2016. The company has various studies demonstrating the reversal of fibrosis and biomarker engagements.

Visit: http://www.complexarx.com
Connect with Complexa on partnering360®

Biotech Showcase™ 2016
Comprehensive Biomarker Center GmbH
Comprehensive Biomarker Center GmbH
Heidelberg, Germany
CBC is developing a new generation of diagnostics for personalized medicine, using microRNA diagnostic biomarkers for early detection and longitudinal monitoring of disease an...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Comprehensive Biomarker Center GmbH

Comprehensive Biomarker Center GmbH is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 9:15 am. Room Davidson.
Comprehensive Biomarker Center GmbH
Track: E
City: Heidelberg
Country: Germany
Ownership: Private
CBC is developing a new generation of diagnostics for personalized medicine, using microRNA diagnostic biomarkers for early detection and longitudinal monitoring of disease and immune status in whole blood. CBC will use its biomarker platform to enhance partner drug and diagnostic development, while providing access to its extensive IP portfolio.

Visit: http://www.cbioc.com
Connect with Comprehensive Biomarker Center GmbH on partnering360®

Biotech Showcase™ 2016
ContraFect
ContraFect
(NASDAQ:CFRX)
Yonkers, New York, United States
ContraFect is a clinical stage biotechnology company focused on therapeutics for serious, life-threatening infectious diseases. Our lead product, CF-301 is a bacteriophage der...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ContraFect

ContraFect is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 10:00 am. Room Powell.
ContraFect
Track: D
City: Yonkers
State: New York
Country: United States
Ownership: Public
Ticker: CFRX
Stock exchange: NASDAQ
ContraFect is a clinical stage biotechnology company focused on therapeutics for serious, life-threatening infectious diseases. Our lead product, CF-301 is a bacteriophage derived lysin recently concluded Phase 1 targeting the treatment of staph aureus bacteremia. We have an influenza therapeutic based on a cocktail of antibodies in IND enabling studies.

Visit: http://contrafect.com/
Connect with ContraFect on partnering360®

Biotech Showcase™ 2016
ContraVir Pharmaceuticals
ContraVir Pharmaceuticals
(NASDAQ:CTRV)
Edison, New Jersey, United States
ContraVir is developing antiviral therapies with two drug candidates in clinical studies. FV-100, now in Phase 3 trials, is being developed for the treatment of herpes zoster,...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ContraVir Pharmaceuticals

ContraVir Pharmaceuticals is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 4:00 pm. Room Powell.
ContraVir Pharmaceuticals
Track: D
City: Edison
State: New Jersey
Country: United States
Ownership: Public
Ticker: CTRV
Stock exchange: NASDAQ
ContraVir is developing antiviral therapies with two drug candidates in clinical studies. FV-100, now in Phase 3 trials, is being developed for the treatment of herpes zoster, or shingles, and shingles related pain(PHN). ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir DF (Viread®).

Visit: http://www.contravir.com
Connect with ContraVir Pharmaceuticals on partnering360®

Biotech Showcase™ 2016
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc.
(NASDAQ:CRBP)
Norwood, Massachusetts, United States
Corbus is focused on the development of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Its lead product candidate, Resunab™, is cu...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 11:00 am. Room Powell.
Corbus Pharmaceuticals Holdings, Inc.
Track: D
City: Norwood
State: Massachusetts
Country: United States
Ownership: Public
Ticker: CRBP
Stock exchange: NASDAQ
Corbus is focused on the development of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Its lead product candidate, Resunab™, is currently being evaluated in separate Phase 2 clinical studies for the treatment of cystic fibrosis, systemic sclerosis and dermatomyositis with top-line results expected starting 4Q16.

Visit: http://www.corbuspharma.com
Connect with Corbus Pharmaceuticals Holdings, Inc. on partnering360®

Biotech Showcase™ 2016
CorMedix Inc.
(NYSE-M:CRMD)
Bedminster, New Jersey, United States
CorMedix Inc. is a commercial-stage biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of card...


Share this:Email this pageShare this on LinkedInShare this on Twitter

CorMedix Inc.

CorMedix Inc. is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 9:30 am. Room Mission I.
Track: B
City: Bedminster
State: New Jersey
Country: United States
Ownership: Public
Ticker: CRMD
Stock exchange: NYSE-M
CorMedix Inc. is a commercial-stage biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of bloodstream infections and maintenance of catheter patency.

Visit: http://www.cormedix.com

Biotech Showcase™ 2016
Counterpoint Biomedica, LLC
Counterpoint Biomedica, LLC
Santa Monica, California, United States
Counterpoint Biomedica is a clinical stage biopharmaceutical company focused on “Efficient Delivery of Cancer Drugs with Pro-Active Tumor Targeting.” The company developed...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Counterpoint Biomedica, LLC

Counterpoint Biomedica, LLC is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 11:30 am. Room Davidson.
Counterpoint Biomedica, LLC
Track: E
City: Santa Monica
State: California
Country: United States
Ownership: Private
Counterpoint Biomedica is a clinical stage biopharmaceutical company focused on “Efficient Delivery of Cancer Drugs with Pro-Active Tumor Targeting.” The company developed an extensive pipeline of tumor-targeting polypeptides (Onco-Aptamers) to enable widely used anticancer agents to perform with greater efficacy, at lower drug doses, with less toxicity in the clinic.

Visit: http://www.counterpointbiomedica.com
Connect with Counterpoint Biomedica, LLC on partnering360®

Biotech Showcase™ 2016
Cristal Therapeutics
Cristal Therapeutics
Maastricht, Netherlands
Crystal Therapeutics launched a clinical trial with its lead product CriPec docetaxel in Q2 2015. Clinical phase IIa will be started in Q2 2016. The company is planning an inv...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cristal Therapeutics

Cristal Therapeutics is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 11:30 am. Room Hearst.
Cristal Therapeutics
Track: A
City: Maastricht
Country: Netherlands
Ownership: Private
Crystal Therapeutics launched a clinical trial with its lead product CriPec docetaxel in Q2 2015. Clinical phase IIa will be started in Q2 2016. The company is planning an investment round end in Q1 2016 to finalize phase IIa and to start phase IIb.

Visit: http://www.cristaltherapeutics.com
Connect with Cristal Therapeutics on partnering360®

Biotech Showcase™ 2016
CureMeta
CureMeta
Boston, Massachusetts, United States
CureMeta is a pre-clinical biotech company focusing on the development of novel therapeutics for the treatment of aggressive and metastatic solid tumors. We have generated com...


Share this:Email this pageShare this on LinkedInShare this on Twitter

CureMeta

CureMeta is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 3:45 pm. Room Davidson.
CureMeta
Track: E
City: Boston
State: Massachusetts
Country: United States
Ownership: Private
CureMeta is a pre-clinical biotech company focusing on the development of novel therapeutics for the treatment of aggressive and metastatic solid tumors. We have generated compelling in vitro and in vivo proof-of-concept data for our lead ADC therapeutic and are seeking funding for Clinical Phase I trials.

Visit: http://www.curemeta.com
Connect with CureMeta on partnering360®

Biotech Showcase™ 2016
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc.
(NASDAQ:CYCC)
New Providence, New Jersey, United States
Developing oral sapacitabine in a fully enrolled Phase 3 for frontline elderly AML under an SPA with the FDA, also in MDS and BRCA positive solid tumor trials and CDK2/9 inhib...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc. is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 9:30 am. Room Powell.
Cyclacel Pharmaceuticals, Inc.
Track: D
City: New Providence
State: New Jersey
Country: United States
Ownership: Public
Ticker: CYCC
Stock exchange: NASDAQ
Developing oral sapacitabine in a fully enrolled Phase 3 for frontline elderly AML under an SPA with the FDA, also in MDS and BRCA positive solid tumor trials and CDK2/9 inhibitor CYC065 in Phase 1 in solid tumors with utility in both hematological malignancies and solid tumors.

Visit: http://www.cyclacel.com
Connect with Cyclacel Pharmaceuticals, Inc. on partnering360®

Biotech Showcase™ 2016
CymaBay Therapeutics
CymaBay Therapeutics
(NASDAQ:CBAY)
Newark, California, United States
CymaBay is developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate is a Phase 3-ready product ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

CymaBay Therapeutics

CymaBay Therapeutics is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 3:00 pm. Room Powell.
CymaBay Therapeutics
Track: D
City: Newark
State: California
Country: United States
Ownership: Public
Ticker: CBAY
Stock exchange: NASDAQ
CymaBay is developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate is a Phase 3-ready product candidate for gout that both reduces uric acid and lowers flares. MBX-8025 is in Phase 2 for Homozygous Familial Hypercholesterolemia and Primary Biliary Cholangitis.

Visit: http://cymabay.com
Connect with CymaBay Therapeutics on partnering360®

Biotech Showcase™ 2016
Cytocentrics, Inc
Cytocentrics, Inc
San Antonio, Texas, United States
This is a commercial stage company whose products are used for safety pharmacology and precision medicine using superior ion channel analytics and the equipment is being used ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cytocentrics, Inc

Cytocentrics, Inc is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 3:45 pm. Room Hearst.
Cytocentrics, Inc
Track: A
City: San Antonio
State: Texas
Country: United States
Ownership: Private
This is a commercial stage company whose products are used for safety pharmacology and precision medicine using superior ion channel analytics and the equipment is being used by the FDA in its furtherance of the CiPA initiative. This is a series A fund raise and we are cash flow positive

Visit: http://www.cytocentrics.com
Connect with Cytocentrics, Inc on partnering360®

Biotech Showcase™ 2016
Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc.
(NASDAQ:CYTX)
San Diego, California, United States
Cytori Therapeutics is a cell therapy company that is uniquely positioned for regulatory and commercial success in the next few years based on our platform technology, two lea...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cytori Therapeutics, Inc.

Cytori Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 4:30 pm. Room Mission I.
Cytori Therapeutics, Inc.
Track: B
City: San Diego
State: California
Country: United States
Ownership: Public
Ticker: CYTX
Stock exchange: NASDAQ
Cytori Therapeutics is a cell therapy company that is uniquely positioned for regulatory and commercial success in the next few years based on our platform technology, two leading late phase development programs, and current regulatory positions. Our lead programs address knee pain in osteoarthritis and hand dysfunction in scleroderma.

Visit: http://www.cytori.com
Connect with Cytori Therapeutics, Inc. on partnering360®

Biotech Showcase™ 2016
CytoSorbents Corporation
CytoSorbents Corporation
(NASDAQ:CTSO)
Monmouth Junction, New Jersey
CytoSorbents Corporation (NASDAQ: CTSO) is a critical care immunotherapy company commercializing its CytoSorb blood purification technology in 32 countries worldwide to treat ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

CytoSorbents Corporation

CytoSorbents Corporation is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 9:00 am. Room Mission I.
CytoSorbents Corporation
Track: B
City: Monmouth Junction
Country: New Jersey
Ownership: Public
Ticker: CTSO
Stock exchange: NASDAQ
CytoSorbents Corporation (NASDAQ: CTSO) is a critical care immunotherapy company commercializing its CytoSorb blood purification technology in 32 countries worldwide to treat life-threatening illnesses. The technology is based on biocompatible, highly porous polymer beads that actively remove inflammatory toxins from the body that can cause dangerous and often deadly inflammation.

Visit: http://cytosorb-therapy.com/
Connect with CytoSorbents Corporation on partnering360®

Biotech Showcase™ 2016
DanDrit
(OTCQB:DDRT)
Copenhagen, New York, United States
A clinical-stage company developing the world’s first vaccine against colorectal cancer. DanDrit runs VIVA, a phase III clinical trial multicenter to assess the capability o...


Share this:Email this pageShare this on LinkedInShare this on Twitter

DanDrit

DanDrit is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 2:00 pm. Room Powell.
Track: D
City: Copenhagen
State: New York
Country: United States
Ownership: Public
Ticker: DDRT
Stock exchange: OTCQB
A clinical-stage company developing the world’s first vaccine against colorectal cancer. DanDrit runs VIVA, a phase III clinical trial multicenter to assess the capability of its lead compound MCV to delay relapse of colorectal cancer after resection and chemotherapy (PI: Pr Sobrero, Genova; chair IDMC: Pr.Axel Grothey, Mayo Clinic).

Visit: http://www.dandrit.com
Connect with DanDrit on partnering360®

Biotech Showcase™ 2016
DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc.
(OTCQX:DMPI)
Vancouver, British Columbia, Canada
DelMar is developing new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. Its lead product cand...


Share this:Email this pageShare this on LinkedInShare this on Twitter

DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 11:00 am. Room Mission II.
DelMar Pharmaceuticals, Inc.
Track: C
City: Vancouver
State: British Columbia
Country: Canada
Ownership: Public
Ticker: DMPI
Stock exchange: OTCQX
DelMar is developing new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. Its lead product candidate, VAL-083, is currently in Phase II as a potential treatment for refractory GBM. The Company expects to commence registration-directed studies in GBM in 2016.

Visit: http://www.delmarpharma.com
Connect with DelMar Pharmaceuticals, Inc. on partnering360®

Biotech Showcase™ 2016
Deltanoid Pharmaceuticals, Inc.
Deltanoid Pharmaceuticals, Inc.
Madison, Wisconson, United States
Deltanoid: Development stage company advancing a substantially de-risked lead program with best-in-class product profile in the $Billion+ secondary hyperparathyroidism ESRD ma...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Deltanoid Pharmaceuticals, Inc.

Deltanoid Pharmaceuticals, Inc. is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 8:15 am. Room Davidson.
Deltanoid Pharmaceuticals, Inc.
Track: E
City: Madison
State: Wisconson
Country: United States
Ownership: Private
Deltanoid: Development stage company advancing a substantially de-risked lead program with best-in-class product profile in the $Billion+ secondary hyperparathyroidism ESRD market with expanded potential in the much larger upstream CKD market and with additional early stage compounds addressing unmet needs in the larger markets of osteoporosis and acne.

Visit: http://www.deltanoid.com

Biotech Showcase™ 2016
DesignMedix, Inc.
Portland, Oregon, United States
DesignMedix, Inc. develops drugs that overcome drug-resistance in globally important infectious diseases including malaria and bacterial diseases. It's lead malaria product is...


Share this:Email this pageShare this on LinkedInShare this on Twitter

DesignMedix, Inc.

DesignMedix, Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 3:15 pm. Room Davidson.
Track: E
City: Portland
State: Oregon
Country: United States
Ownership: Private
DesignMedix, Inc. develops drugs that overcome drug-resistance in globally important infectious diseases including malaria and bacterial diseases. It's lead malaria product is in preparation for Phase I clinical trials.

Visit: http://www.designmedix.com/
Connect with DesignMedix, Inc. on partnering360®

Biotech Showcase™ 2016
Diapin Therapeutics
Diapin Therapeutics
Ann Arbor, Michigan, United States
Diapin Therapeutics is focused on developing novel therapies for type 2 diabetes (T2D) and complications thereof (T2D). The lead compound (DT-110) is the orally active 3 amino...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Diapin Therapeutics

Diapin Therapeutics is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 10:15 am. Room Hearst.
Diapin Therapeutics
Track: A
City: Ann Arbor
State: Michigan
Country: United States
Ownership: Private
Diapin Therapeutics is focused on developing novel therapies for type 2 diabetes (T2D) and complications thereof (T2D). The lead compound (DT-110) is the orally active 3 amino acid peptide , which is schedule to begin preclinical toxicology studies shortly. Diapin has additional IP for an active form of PlavixTM.

Visit: http://www.diapin.com
Connect with Diapin Therapeutics on partnering360®

Biotech Showcase™ 2016
Diffusion Pharmaceuticals LLC
Diffusion Pharmaceuticals LLC
(OTC:DFFN)
Charlottesville, Virginia, United States
Diffusion is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients. Diffusion’s lead drug, TSC, is designed to re-oxygenate trea...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Diffusion Pharmaceuticals LLC

Diffusion Pharmaceuticals LLC is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 4:00 pm. Room Mission I.
Diffusion Pharmaceuticals LLC
Track: B
City: Charlottesville
State: Virginia
Country: United States
Ownership: Public
Ticker: DFFN
Stock exchange: OTC
Diffusion is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients. Diffusion’s lead drug, TSC, is designed to re-oxygenate treatment-resistant hypoxic tissue present in many solid cancerous tumors and render the cancer cells more vulnerable to radiation and chemotherapy, without introducing any serious side effects.

Visit: http://www.diffusionpharma.com
Connect with Diffusion Pharmaceuticals LLC on partnering360®

Biotech Showcase™ 2016
Dipexium
Dipexium
(NASDAQ:DPRX)
New York, New York, United States
Dipexium is conducting Pivotal Phase 3 Clinical Trials on its novel, topical antibiotic cream targeting treatment of mild infections of diabetic foot ulcers as well as other s...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Dipexium

Dipexium is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 10:00 am. Room Mission II.
Dipexium
Track: C
City: New York
State: New York
Country: United States
Ownership: Public
Ticker: DPRX
Stock exchange: NASDAQ
Dipexium is conducting Pivotal Phase 3 Clinical Trials on its novel, topical antibiotic cream targeting treatment of mild infections of diabetic foot ulcers as well as other skin infections including those caused by resistant bacteria or "superbugs." Dipexium targets program completion in 1H16 and related regulatory submissions in 2H16.

Visit: http://www.dipexiumpharmaceuticals.com
Connect with Dipexium on partnering360®

Biotech Showcase™ 2016
DiscGenics
DiscGenics
Salt Lake City, Utah, United States
DiscGenics is a biotechnology company developing advanced spinal therapeutics to treat patients with diseases of the intervertebral disc. We are currently developing IDCT, a n...


Share this:Email this pageShare this on LinkedInShare this on Twitter

DiscGenics

DiscGenics is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 2:00 pm. Room Davidson.
DiscGenics
Track: E
City: Salt Lake City
State: Utah
Country: United States
Ownership: Private
DiscGenics is a biotechnology company developing advanced spinal therapeutics to treat patients with diseases of the intervertebral disc. We are currently developing IDCT, a novel off-the-shelf injectable therapeutic based on regenerative medicine and progenitor cell science to treat pain associated with degenerative disc disease.

Visit: http://discgenics.com
Connect with DiscGenics on partnering360®

Biotech Showcase™ 2016
Elasmogen Ltd
Elasmogen Ltd
Aberdeen, United Kingdom
Elasmogen Ltd is a therapeutic biologics company developing antibody-like domains (soloMERsTM) for the treatment of autoimmune inflammatory disease. The small size and remarka...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Elasmogen Ltd

Elasmogen Ltd is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 8:30 am. Room Davidson.
Elasmogen Ltd
Track: E
City: Aberdeen
Country: United Kingdom
Ownership: Private
Elasmogen Ltd is a therapeutic biologics company developing antibody-like domains (soloMERsTM) for the treatment of autoimmune inflammatory disease. The small size and remarkable stability of soloMERsTM facilitate site-specific delivery directly to the point of clinical need; topical administration for treatment of Uveitis and gut-specific delivery for the treatment of IBD.
Connect with Elasmogen Ltd on partnering360®

Biotech Showcase™ 2016
Embera NeuroTherapeutics, Inc.
Embera NeuroTherapeutics, Inc.
Sudbury, Massachusetts, United States
Embera is developing a novel, patented drug combination (EMB-001) to address significant unmet needs in smoking cessation and cocaine dependence whose markets together exceed ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Embera NeuroTherapeutics, Inc.

Embera NeuroTherapeutics, Inc. is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 2:30 pm. Room Davidson.
Embera NeuroTherapeutics, Inc.
Track: E
City: Sudbury
State: Massachusetts
Country: United States
Ownership: Private
Embera is developing a novel, patented drug combination (EMB-001) to address significant unmet needs in smoking cessation and cocaine dependence whose markets together exceed $2B. Embera has completed a Phase 1 safety & PK study in smokers and is raising a $17M Series B financing to fund Phase 1B&2 development.

Visit: http://www.emberaneuro.com
Connect with Embera NeuroTherapeutics, Inc. on partnering360®

Biotech Showcase™ 2016
ENB Therapeutics, LLC
ENB Therapeutics, LLC
New York, New York, United States
ENB Therapeutics is a pre-clinical stage company focused on treating brain cancers and other cancers including brain melanoma and glioblastoma. It's lead product is in the IND...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ENB Therapeutics, LLC

ENB Therapeutics, LLC is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 8:45 am. Room Davidson.
ENB Therapeutics, LLC
Track: E
City: New York
State: New York
Country: United States
Ownership: Private
ENB Therapeutics is a pre-clinical stage company focused on treating brain cancers and other cancers including brain melanoma and glioblastoma. It's lead product is in the IND stage and is anticipated to be awarded orphan drug status by the FDA as of January of 2016.

Visit: http://www.enbpharma.com
Connect with ENB Therapeutics, LLC on partnering360®

Biotech Showcase™ 2016
Enumeral Biomedical Holdings
Enumeral Biomedical Holdings
(OTCQB:ENUM)
Cambridge, Massachusetts, United States
Enumeral is developing a potential ‘best-in-class’ anti-PD-1 antibody with novel biochemical and immunomodulatory properties. The Company uses its proprietary immunotherap...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Enumeral Biomedical Holdings

Enumeral Biomedical Holdings is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 9:30 am. Room Powell.
Enumeral Biomedical Holdings
Track: D
City: Cambridge
State: Massachusetts
Country: United States
Ownership: Public
Ticker: ENUM
Stock exchange: OTCQB
Enumeral is developing a potential ‘best-in-class’ anti-PD-1 antibody with novel biochemical and immunomodulatory properties. The Company uses its proprietary immunotherapy platform to interrogate the tumor immune microenvironment to measure drug effects in a patient-specific manner, providing translational insights to guide development and rational selection of drug combinations for immunotherapy.

Visit: http://www.enumeral.com
Connect with Enumeral Biomedical Holdings on partnering360®

Biotech Showcase™ 2016
Eos Biosciences, Inc.
Century City, California, United States
EOS BioSciences is a pre-clinical Nanomedicines company with a world-wide exclusive license to a novel platform drug targeting technology. The technology is based on self-asse...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Eos Biosciences, Inc.

Eos Biosciences, Inc. is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 4:00 pm. Room Hearst.
Track: A
City: Century City
State: California
Country: United States
Ownership: Private
EOS BioSciences is a pre-clinical Nanomedicines company with a world-wide exclusive license to a novel platform drug targeting technology. The technology is based on self-assembling, biotargeted nanoparticles (Eosomes) that efficiently entrap a chosen therapeutic, specifically localize it to the disease cell, and deliver it to the interior of a target cell.

Visit: http://www.eosbiosciences.com

Biotech Showcase™ 2016
EpiVax, Inc.
EpiVax, Inc.
Providence, Rhode Island, United States
Aceno Biotherapeutics, a joint venture between EpiVax and Schrödinger, two internationally respected organizations, develops improved biologic drugs called Biobetters. Aceno...


Share this:Email this pageShare this on LinkedInShare this on Twitter

EpiVax, Inc.

EpiVax, Inc. is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 4:00 pm. Room Davidson.
EpiVax, Inc.
Track: E
City: Providence
State: Rhode Island
Country: United States
Ownership: Private
Aceno Biotherapeutics, a joint venture between EpiVax and Schrödinger, two internationally respected organizations, develops improved biologic drugs called Biobetters. Aceno’s goal is to produce new drugs that reduce the risk of immunogenicity by combining the unique expertise and proprietary computational technologies developed at EpiVax and Schrödinger.

Visit: http://www.epivax.com
Connect with EpiVax, Inc. on partnering360®

Biotech Showcase™ 2016
Erytech Pharma
Erytech Pharma
(EURONEXT:ERYP)
Lyon, France
ERYTECH Pharma develops ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs. The company has a production unit located...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Erytech Pharma

Erytech Pharma is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 3:00 pm. Room Mission I.
Erytech Pharma
Track: B
City: Lyon
Country: France
Ownership: Public
Ticker: ERYP
Stock exchange: EURONEXT
ERYTECH Pharma develops ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs. The company has a production unit located in Lyon with “Pharmaceutical Establishment” status.

Visit: http://erytech.com/home/
Connect with Erytech Pharma on partnering360®

Biotech Showcase™ 2016
Espero Pharmaceuticals, Inc.
Jacksonville, Florida, United States
Espero Pharmaceuticals, Inc. is an emerging growth specialty pharmaceutical company engaged in maximizing the commercial value of proven treatments that improve the quality of...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Espero Pharmaceuticals, Inc.

Espero Pharmaceuticals, Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 2:45 pm. Room Davidson.
Track: E
City: Jacksonville
State: Florida
Country: United States
Ownership: Private
Espero Pharmaceuticals, Inc. is an emerging growth specialty pharmaceutical company engaged in maximizing the commercial value of proven treatments that improve the quality of life for patients. The Company owns the exclusive US marketing rights to two prescription cardiovascular drugs that deliver fast-acting therapeutic benefits.

Visit: http://esperopharma.com
Connect with Espero Pharmaceuticals, Inc. on partnering360®

Biotech Showcase™ 2016
Euclises
Euclises
St. Louis, Missouri, United States
Euclises Pharmaceuticals, Inc., is a biopharmaceutical company that has discovered and is developing novel oral 3rd generation potent and selective COX-2 inhibitors for the tr...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Euclises

Euclises is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 3:00 pm. Room Davidson.
Euclises
Track: E
City: St. Louis
State: Missouri
Country: United States
Ownership: Private
Euclises Pharmaceuticals, Inc., is a biopharmaceutical company that has discovered and is developing novel oral 3rd generation potent and selective COX-2 inhibitors for the treatment of various cancers that are dependent on COX-2/PGE-2. The lead compound has been shown to significantly slow tumor growth in multiple animal models of cancer.

Visit: http://www.euclises.com
Connect with Euclises on partnering360®

Biotech Showcase™ 2016
ExCellThera
ExCellThera
Montreal, Quebec, Canada
ExCellThera is a clinical-stage company developing a best-in-class platform for the ex vivo expansion of blood-derived progenitor and long-term stem cells for allogeneic stem ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ExCellThera

ExCellThera is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 5:00 pm. Room Hearst.
ExCellThera
Track: A
City: Montreal
State: Quebec
Country: Canada
Ownership: Private
ExCellThera is a clinical-stage company developing a best-in-class platform for the ex vivo expansion of blood-derived progenitor and long-term stem cells for allogeneic stem cell transplantation, and for gene therapy applications. The company has recently initiated a multi-centre Phase I/II trial in up to 25 patients undergoing stem cell transplantation.

Visit: http://www.excellthera.ca
Connect with ExCellThera on partnering360®

Biotech Showcase™ 2016
Exicure
Exicure
Skokie, Illinois, United States
Exicure is a biopharmaceutical company developing a new class of nucleic acid “Spherical Nucleic Acid (SNA).” SNAs provide a 3D presentation of oligonucleotides, which are...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Exicure

Exicure is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 10:30 am. Room Davidson.
Exicure
Track: E
City: Skokie
State: Illinois
Country: United States
Ownership: Private
Exicure is a biopharmaceutical company developing a new class of nucleic acid “Spherical Nucleic Acid (SNA).” SNAs provide a 3D presentation of oligonucleotides, which are able to enter cells and tissues without the use of transfection agents. These structures have demonstrated in vivo potential in cancer and skin disease models.

Visit: http://www.Exicuretx.com
Connect with Exicure on partnering360®

Biotech Showcase™ 2016
Factor Therapeutics
Factor Therapeutics
(ASX:TIS)
Brisbane, Queensland, Australia
Factor Therapeutics is a clinical-stage biotechnology company dedicated to the development of advanced wound care products. Our technology uses targeted growth factors to tran...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Factor Therapeutics

Factor Therapeutics is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 3:00 pm. Room Mission II.
Factor Therapeutics
Track: C
City: Brisbane
State: Queensland
Country: Australia
Ownership: Public
Ticker: TIS
Stock exchange: ASX
Factor Therapeutics is a clinical-stage biotechnology company dedicated to the development of advanced wound care products. Our technology uses targeted growth factors to transform the healing process and has application in both chronic wounds and also specialty post-surgical settings such as ocular wound care. We are an Australian public company.

Visit: http://tissuetherapies.com/
Connect with Factor Therapeutics on partnering360®

Biotech Showcase™ 2016
Fate Therapeutics
Fate Therapeutics
(NASDAQ:FATE)
San Diego, California, United States
Developing programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. Cell-based product pipeline is comprised of off-the-shelf immuno-oncology t...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Fate Therapeutics

Fate Therapeutics is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 3:00 pm. Room Mission I.
Fate Therapeutics
Track: B
City: San Diego
State: California
Country: United States
Ownership: Public
Ticker: FATE
Stock exchange: NASDAQ
Developing programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. Cell-based product pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation.

Visit: http://fatetherapeutics.com/
Connect with Fate Therapeutics on partnering360®

Biotech Showcase™ 2016
Feldan
Feldan
Quebec, Quebec, Canada
Feldan is a preclinical company with a disruptive platform to develop regenerative medicine therapeutic applications based on the delivery of functional protein inside the cel...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Feldan

Feldan is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 3:45 pm. Room Hearst.
Feldan
Track: A
City: Quebec
State: Quebec
Country: Canada
Ownership: Private
Feldan is a preclinical company with a disruptive platform to develop regenerative medicine therapeutic applications based on the delivery of functional protein inside the cells to induce genetic modifications or to modulate gene expression or cell physiology apply in cell therapy & genome modified cell therapy.

Visit: http://www.feldan.com
Connect with Feldan on partnering360®

Biotech Showcase™ 2016
Felicitex Therapeutics
Watertown, Massachusetts, United States
Felicitex Therapeutics is a preclinical stage focused on treating cancer. Its lead product is currently in late preclinical stage for the treatment of pancreatic and lung canc...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Felicitex Therapeutics

Felicitex Therapeutics is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 8:00 am. Room Hearst.
Track: A
City: Watertown
State: Massachusetts
Country: United States
Ownership: Private
Felicitex Therapeutics is a preclinical stage focused on treating cancer. Its lead product is currently in late preclinical stage for the treatment of pancreatic and lung cancers.

Visit: http://www.felicitex.com
Connect with Felicitex Therapeutics on partnering360®

Biotech Showcase™ 2016
Fennec Pharma
Fennec Pharma
(TSX:FRX)
Research Triangle Park, North Carolina, United States
Fennec Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity i...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Fennec Pharma

Fennec Pharma is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 11:00 am. Room Powell.
Fennec Pharma
Track: D
City: Research Triangle Park
State: North Carolina
Country: United States
Ownership: Public
Ticker: FRX
Stock exchange: TSX
Fennec Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients. STS has received Orphan Drug Designation in the US in this setting. For more information, please visit www.fennecpharma.com.

Visit: http://www.fennecpharma.com
Connect with Fennec Pharma on partnering360®

Biotech Showcase™ 2016
FluoroFinder
FluoroFinder
Broomfield, Colorado, United States
FluoroFinder is developing a portfolio of Software as a Service (SaaS) experiment design tools that dramatically improve a medical researcher’s productivity and quality, whi...


Share this:Email this pageShare this on LinkedInShare this on Twitter

FluoroFinder

FluoroFinder is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 9:00 am. Room Davidson.
FluoroFinder
Track: E
City: Broomfield
State: Colorado
Country: United States
Ownership: Private
FluoroFinder is developing a portfolio of Software as a Service (SaaS) experiment design tools that dramatically improve a medical researcher’s productivity and quality, while reducing costs. The company’s first online experiment design tool has been rolled out to over 175 research facilities and pharma labs since commercial launch.

Visit: http://www.fluorofinder.com
Connect with FluoroFinder on partnering360®

Biotech Showcase™ 2016
Forendo Pharma
Forendo Pharma
Turku, Finland
Forendo Pharma is a drug development company focused on novel therapies for women's and men's health. The core competence of the team resides in tissue specific regulation of ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Forendo Pharma

Forendo Pharma is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 3:30 pm. Room Hearst.
Forendo Pharma
Track: A
City: Turku
Country: Finland
Ownership: Private
Forendo Pharma is a drug development company focused on novel therapies for women's and men's health. The core competence of the team resides in tissue specific regulation of sex hormone effects. The current lead programs are: Fispemifene (phase 2b) for the treatment of secondary hypogonadism and HSD17B inhibitor for endometriosis.

Visit: http://forendo.com/
Connect with Forendo Pharma on partnering360®

Biotech Showcase™ 2016
Forge Therapeutics
Forge Therapeutics
San Diego, California, United States
Forge Therapeutics is a biotechnology company developing innovative medicines using a breakthrough drug discovery platform targeting metalloproteins.


Share this:Email this pageShare this on LinkedInShare this on Twitter

Forge Therapeutics

Forge Therapeutics is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 2:15 pm. Room Davidson.
Forge Therapeutics
Track: E
City: San Diego
State: California
Country: United States
Ownership: Private
Forge Therapeutics is a biotechnology company developing innovative medicines using a breakthrough drug discovery platform targeting metalloproteins.

Visit: http://ForgeTherapeutics.com

Biotech Showcase™ 2016
Formation Biologics
Houston, Texas, United States
Formation Biologics is a venture-backed company that engineers immunotherapeutics and immunoconjugates that possess potent and selective anti-cancer activity. It was formed in...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Formation Biologics

Formation Biologics is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 5:15 pm. Room Hearst.
Track: A
City: Houston
State: Texas
Country: United States
Ownership: Private
Formation Biologics is a venture-backed company that engineers immunotherapeutics and immunoconjugates that possess potent and selective anti-cancer activity. It was formed in 2011 as a spin out from YM BioSciences and is based on technologies co-developed with the National Research Council and other research centers of excellence.

Visit: http://www.formationbiologics.com

Biotech Showcase™ 2016
Fusion Pharmaceuticals
Fusion Pharmaceuticals
Hamilton, Ontario, Canada
Fusion’s novel drug candidates combine targeted, internalizing delivery vehicles with the potent killing power of the high-energy alpha-emitting radioactive isotope, actiniu...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Fusion Pharmaceuticals

Fusion Pharmaceuticals is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 11:15 am. Room Hearst.
Fusion Pharmaceuticals
Track: A
City: Hamilton
State: Ontario
Country: Canada
Ownership: Private
Fusion’s novel drug candidates combine targeted, internalizing delivery vehicles with the potent killing power of the high-energy alpha-emitting radioactive isotope, actinium-225, to treat solid tumor cancers. Having achieved POC in a Phase 1 trial, Fusion is now moving forward with a Phase 1/2 efficacy study for its lead drug, FPX-01.

Visit: http://www.fusionpharma.com
Connect with Fusion Pharmaceuticals on partnering360®

Biotech Showcase™ 2016
Galmed Pharmaceuticals
Galmed Pharmaceuticals
(NASDAQ:GLMD)
New York, New York, United States
Galmed is a clinical-stage biopharmaceutical company focused on the development of a novel, once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis/NASH and...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Galmed Pharmaceuticals

Galmed Pharmaceuticals is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 10:30 am. Room Mission I.
Galmed Pharmaceuticals
Track: B
City: New York
State: New York
Country: United States
Ownership: Public
Ticker: GLMD
Stock exchange: NASDAQ
Galmed is a clinical-stage biopharmaceutical company focused on the development of a novel, once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis/NASH and other liver diseases. Galmed believes that its product candidate, Aramchol(tm), has the potential to be a disease modifying liver disorders, which constitutes a large unmet medical need.

Visit: http://www.galmedpharma.com
Connect with Galmed Pharmaceuticals on partnering360®

Biotech Showcase™ 2016
Glactone Pharma
Helsingborg, Sweden
Glactone Pharma is a preclinical stage company developing novel small molecule drugs that directly target the transcription factor STAT3. The company is focused on reversing t...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Glactone Pharma

Glactone Pharma is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 4:45 pm. Room Davidson.
Track: E
City: Helsingborg
Country: Sweden
Ownership: Private
Glactone Pharma is a preclinical stage company developing novel small molecule drugs that directly target the transcription factor STAT3. The company is focused on reversing tumor induced immunosuppression to enhance the efficacy and response rate of immunotherapies and reversing anti-androgen resistance in advanced prostate cancer.

Visit: http://www.glactone.com
Connect with Glactone Pharma on partnering360®

Biotech Showcase™ 2016
Global Cancer Diagnostics Inc.
Global Cancer Diagnostics Inc.
Tempe, Arizona, United States
Global Cancer Diagnostics is focused on screening for lung cancer and other cancers for early detection. Early detection of lung cancer increases survival rate from 4% to 82%....


Share this:Email this pageShare this on LinkedInShare this on Twitter

Global Cancer Diagnostics Inc.

Global Cancer Diagnostics Inc. is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 9:15 am. Room Davidson.
Global Cancer Diagnostics Inc.
Track: E
City: Tempe
State: Arizona
Country: United States
Ownership: Private
Global Cancer Diagnostics is focused on screening for lung cancer and other cancers for early detection. Early detection of lung cancer increases survival rate from 4% to 82%. Early detection of cancer provides life saving tools. The company's CLIA certified laboratory is the center of the Company

Visit: http://www.globalcancerdx.com
Connect with Global Cancer Diagnostics Inc. on partnering360®

Biotech Showcase™ 2016
Globavir
Globavir
Los Altos, California, United States
Globavir is developing drugs for immuno-oncology and infectious diseases with two immuno-oncology drugs and one infectious disease program in clinic before the end of 2016 bas...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Globavir

Globavir is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 11:00 am. Room Davidson.
Globavir
Track: E
City: Los Altos
State: California
Country: United States
Ownership: Private
Globavir is developing drugs for immuno-oncology and infectious diseases with two immuno-oncology drugs and one infectious disease program in clinic before the end of 2016 based out of a chem-informatics platform developed at Stanford University. We also have partnered one of our oncology program in 2015 with Sorrento/ Nantworks.

Visit: http://www.globavir.com
Connect with Globavir on partnering360®

Biotech Showcase™ 2016
Gordian Biotechnologies Inc
West Palm Beach, Forida, United States
Gordian Biotechnologies is addressing antibiotic resistance, which remains an urgent unmet need, by developing a first-in-class non-covalently bound reversible beta-lactamase ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Gordian Biotechnologies Inc

Gordian Biotechnologies Inc is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 8:00 am. Room Davidson.
Track: E
City: West Palm Beach
State: Forida
Country: United States
Ownership: Private
Gordian Biotechnologies is addressing antibiotic resistance, which remains an urgent unmet need, by developing a first-in-class non-covalently bound reversible beta-lactamase inhibitor. Our lead product, GOR-101, attacks the resistance mechanism of the bacteria making them once again susceptible to existing antibiotics. Established market, established approval pathway.

Visit: http://Gordianbio.com

Biotech Showcase™ 2016
GrayBug
GrayBug
Redwood City, California, United States
GrayBug is an ocular drug delivery company founded with technology licensed from the Wilmer Eye Institute. We are developing a novel depot formulation of an anti-VEGF/anti-PDG...


Share this:Email this pageShare this on LinkedInShare this on Twitter

GrayBug

GrayBug is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 9:45 am. Room Davidson.
GrayBug
Track: E
City: Redwood City
State: California
Country: United States
Ownership: Private
GrayBug is an ocular drug delivery company founded with technology licensed from the Wilmer Eye Institute. We are developing a novel depot formulation of an anti-VEGF/anti-PDGF dual inhibitor product dosed once every 4-6 months for the treatment of wet AMD.

Visit: http://www.graybug.com

Biotech Showcase™ 2016
GRI Bio, Inc.
GRI Bio, Inc.
San Diego, California, United States
GRI Bio is a clinical stage development company, currently in phase 2, developing therapies that target the activity of Natural Killer T (NKT) cells for liver and fibrotic dis...


Share this:Email this pageShare this on LinkedInShare this on Twitter

GRI Bio, Inc.

GRI Bio, Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 4:00 pm. Room Hearst.
GRI Bio, Inc.
Track: A
City: San Diego
State: California
Country: United States
Ownership: Private
GRI Bio is a clinical stage development company, currently in phase 2, developing therapies that target the activity of Natural Killer T (NKT) cells for liver and fibrotic disease. GRI's program are in development for NASH and rare liver diseases, such as autoimmune hepatitis and PSC.

Visit: http://www.gribio.com
Connect with GRI Bio, Inc. on partnering360®

Biotech Showcase™ 2016
Hansa Medical AB
Hansa Medical AB
(NASDAQ:HMED)
Lund, Sweden
Hansa Medical is a biopharmaceutical company focused on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Hansa Medical AB

Hansa Medical AB is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 3:30 pm. Room Powell.
Hansa Medical AB
Track: D
City: Lund
Country: Sweden
Ownership: Public
Ticker: HMED
Stock exchange: NASDAQ
Hansa Medical is a biopharmaceutical company focused on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. A successful Phase II was finalised with lead candidate IdeS during 2015 and several additional Phase II trials are ongoing or planned.

Visit: http://www.hansamedical.com
Connect with Hansa Medical AB on partnering360®

Biotech Showcase™ 2016
Harvard Apparatus Regenerative Technology, Inc.
Harvard Apparatus Regenerative Technology, Inc.
(NASDAQ:HART)
Holliston, Massachusetts, United States
Maker of bioengineered organ implants for life-threatening conditions. Our technology platform to be used to restore function to the esophagus and the airways (trachea and bro...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Harvard Apparatus Regenerative Technology, Inc.

Harvard Apparatus Regenerative Technology, Inc. is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 2:00 pm. Room Mission I.
Harvard Apparatus Regenerative Technology, Inc.
Track: B
City: Holliston
State: Massachusetts
Country: United States
Ownership: Public
Ticker: HART
Stock exchange: NASDAQ
Maker of bioengineered organ implants for life-threatening conditions. Our technology platform to be used to restore function to the esophagus and the airways (trachea and bronchus), primarily to address cancer. Six patients treated under compassionate use with our first generation trachea product, which also was granted orphan status in U.S.

Visit: http://www.hartregen.com
Connect with Harvard Apparatus Regenerative Technology, Inc. on partnering360®

Biotech Showcase™ 2016
Healios K.K.
Healios K.K.
(TSE:4593)
Tokyo, Japan
Founded in Tokyo in 2011, Healios KK engages in the development and sale of ophthalmological surgery adjuvants. It does research, develops and manufactures cell therapy and re...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Healios K.K.

Healios K.K. is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 4:30 pm. Room Mission I.
Healios K.K.
Track: B
City: Tokyo
Country: Japan
Ownership: Public
Ticker: 4593
Stock exchange: TSE
Founded in Tokyo in 2011, Healios KK engages in the development and sale of ophthalmological surgery adjuvants. It does research, develops and manufactures cell therapy and regenerative medicine products, and aims to commercialize pharmaceutical hiPSC derived RPE cell transplantation. Sales and net income in 2014 were US$2.6mm and (US$4.5mm) respectively.

Visit: https://www.healios.co.jp/en/
Connect with Healios K.K. on partnering360®

Biotech Showcase™ 2016
Heat Biologics
Heat Biologics
(NASDAQ:HTBX)
Heat Biologics is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Currently, Heat is conducting two clinical t...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Heat Biologics

Heat Biologics is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 11:30 am. Room Mission II.
Heat Biologics
Track: C
Ownership: Public
Ticker: HTBX
Stock exchange: NASDAQ
Heat Biologics is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Currently, Heat is conducting two clinical trials, with its lead program in Phase 2 being evaluated for non-muscle invasive bladder cancer.

Visit: http://www.heatbio.com/
Connect with Heat Biologics on partnering360®

Biotech Showcase™ 2016
HedgePath Pharmaceuticals, Inc.
HedgePath Pharmaceuticals, Inc.
(OTCQB:HPPI)
Tampa, Florida, United States
HedgePath Pharmaceuticals is a clinical stage biopharmaceutical company that is seeking to discover, develop and commercialize innovative therapeutics for patients with certai...


Share this:Email this pageShare this on LinkedInShare this on Twitter

HedgePath Pharmaceuticals, Inc.

HedgePath Pharmaceuticals, Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 9:00 am. Room Mission II.
HedgePath Pharmaceuticals, Inc.
Track: C
City: Tampa
State: Florida
Country: United States
Ownership: Public
Ticker: HPPI
Stock exchange: OTCQB
HedgePath Pharmaceuticals is a clinical stage biopharmaceutical company that is seeking to discover, develop and commercialize innovative therapeutics for patients with certain cancers. Our preliminary focus is on the development of therapies for skin, lung and prostate cancers with the first indication targeting basal cell carcinoma in patients with BCCNS.

Visit: http://hedgepathpharma.com
Connect with HedgePath Pharmaceuticals, Inc. on partnering360®

Biotech Showcase™ 2016
Helomics Corporation
Helomics Corporation
Pittsburgh, Pennsylvania, United States
Helomics® is a comprehensive personalized healthcare company in oncology. Helomics provides comprehensive personalized tumor profiling utilizing a proprietary set of laborato...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Helomics Corporation

Helomics Corporation is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 2:30 pm. Room Davidson.
Helomics Corporation
Track: E
City: Pittsburgh
State: Pennsylvania
Country: United States
Ownership: Private
Helomics® is a comprehensive personalized healthcare company in oncology. Helomics provides comprehensive personalized tumor profiling utilizing a proprietary set of laboratory platforms that leverage both live and fixed cellular analysis. Helomics also provides a Pharma/Biotech Services Division on its live cell platform called PCAP. Please visit: www.helomics.com.

Visit: http://www.helomics.com
Connect with Helomics Corporation on partnering360®

Biotech Showcase™ 2016
Histogenics
Histogenics
(NASDAQ:HSGX)
Waltham, Massachusetts, United States
Histogenics is a regenerative medicine company developing products for tissue and cartilage repair. We combine expertise in cell processing, scaffolding, tissue engineering, b...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Histogenics

Histogenics is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 11:30 am. Room Mission I.
Histogenics
Track: B
City: Waltham
State: Massachusetts
Country: United States
Ownership: Public
Ticker: HSGX
Stock exchange: NASDAQ
Histogenics is a regenerative medicine company developing products for tissue and cartilage repair. We combine expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide superior therapeutic solutions for unmet musculoskeletal needs. Our lead product, NeoCart, is currently enrolling in a Phase III clinical trial.

Visit: http://www.histogenics.com
Connect with Histogenics on partnering360®

Biotech Showcase™ 2016
HitGen Ltd
HitGen Ltd
Chengdu, Sichuan, China
The formation of the company has received major investment from China Chengdu Import and Export Group Co. Ltd, and enterprise grant support from Chengdu High Tech Zone.


Share this:Email this pageShare this on LinkedInShare this on Twitter

HitGen Ltd

HitGen Ltd is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 4:30 pm. Room Hearst.
HitGen Ltd
Track: A
City: Chengdu
State: Sichuan
Country: China
Ownership: Private
The formation of the company has received major investment from China Chengdu Import and Export Group Co. Ltd, and enterprise grant support from Chengdu High Tech Zone.

Visit: http://www.hitgen.com
Connect with HitGen Ltd on partnering360®

Biotech Showcase™ 2016
Hydra BioSciences, Inc.
Hydra BioSciences, Inc.
Cambridge, Massachusetts, United States
Hydra Biosciences (Hydra) aims to use its expertise in novel TRP ion channels to discover and develop medicines that improve outcomes and minimize the side effects for people ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Hydra BioSciences, Inc.

Hydra BioSciences, Inc. is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 3:15 pm. Room Davidson.
Hydra BioSciences, Inc.
Track: E
City: Cambridge
State: Massachusetts
Country: United States
Ownership: Private
Hydra Biosciences (Hydra) aims to use its expertise in novel TRP ion channels to discover and develop medicines that improve outcomes and minimize the side effects for people with serious diseases and conditions. Hydra’s most advanced medicine is being studied for neuropathic pain and asthma.

Visit: http://www.hydrabiosciences.com
Connect with Hydra BioSciences, Inc. on partnering360®

Biotech Showcase™ 2016
IGXBio
IGXBio
Fairway, Kansas, United States
IGXBio is a clinical stage company. The IND enabling pre-clinical development to date has been largely funded by $21 million of NIH grants, as well as $4 million by private in...


Share this:Email this pageShare this on LinkedInShare this on Twitter

IGXBio

IGXBio is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 4:00 pm. Room Hearst.
IGXBio
Track: A
City: Fairway
State: Kansas
Country: United States
Ownership: Private
IGXBio is a clinical stage company. The IND enabling pre-clinical development to date has been largely funded by $21 million of NIH grants, as well as $4 million by private investors. The company has an open IND for a Phase I/IIa clinical trial with GenePro® immunotherapy in HIV positive patients.

Visit: http://www.igxbio.com
Connect with IGXBio on partnering360®

Biotech Showcase™ 2016
IM Therapeutics
IM Therapeutics
Broomfield, Colorado, United States
IM Therapeutics is a clinical stage immunotherapy company focused on developing small molecule drugs for autoimmune diseases that are associated with certain high risk genes f...


Share this:Email this pageShare this on LinkedInShare this on Twitter

IM Therapeutics

IM Therapeutics is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 10:45 am. Room Hearst.
IM Therapeutics
Track: A
City: Broomfield
State: Colorado
Country: United States
Ownership: Private
IM Therapeutics is a clinical stage immunotherapy company focused on developing small molecule drugs for autoimmune diseases that are associated with certain high risk genes from MHC Class II proteins. Our lead drug, IMT-001, has shown efficacy in Type 1 diabetes patients with DQ8 polymorphisms (60% of patients).

Visit: http://imtherapeutics.com/.
Connect with IM Therapeutics on partnering360®

Biotech Showcase™ 2016
Immunomic Therapeutics
Immunomic Therapeutics
Rockville, Maryland, United States
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company developing and commercializing applications of our LAMP-vax platform which we belie...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Immunomic Therapeutics

Immunomic Therapeutics is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 11:45 am. Room Davidson.
Immunomic Therapeutics
Track: E
City: Rockville
State: Maryland
Country: United States
Ownership: Private
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company developing and commercializing applications of our LAMP-vax platform which we believe is a disruptive technology that has the potential to fundamentally alter how we use vaccines to treat diseases from allergies to cancer.

Visit: http://www.immunomix.com
Connect with Immunomic Therapeutics on partnering360®

Biotech Showcase™ 2016
Impel NeuroPharma
Seattle, California, United States
Impel NeuroPharma is a CNS drug development company utilizing its intranasal Precision Olfactory Delivery (POD) device to enable therapeutics to bypass the blood-brain barrier...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Impel NeuroPharma

Impel NeuroPharma is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 2:30 pm. Room Davidson.
Track: E
City: Seattle
State: California
Country: United States
Ownership: Private
Impel NeuroPharma is a CNS drug development company utilizing its intranasal Precision Olfactory Delivery (POD) device to enable therapeutics to bypass the blood-brain barrier. Impel has a clinical-stage pipeline of both 505(b)2 products and novel biologics, including dihydroergotamine (DHE) for migraine, intranasal insulin for Alzheimer's, and opioid peptides for pain.

Visit: http://www.impelneuropharma.com
Connect with Impel NeuroPharma on partnering360®

Biotech Showcase™ 2016
Imugene
Imugene
(ASX:IMU)
Armadale, Victoria, Australia
Imugene is a clinical stage immuno-oncology in Australia, the lead product is HER-Vaxx, a cancer immunotherapy designed to treat over-express HER-2/neu receptor. In a Ph 1 stu...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Imugene

Imugene is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 4:00 pm. Room Mission II.
Imugene
Track: C
City: Armadale
State: Victoria
Country: Australia
Ownership: Public
Ticker: IMU
Stock exchange: ASX
Imugene is a clinical stage immuno-oncology in Australia, the lead product is HER-Vaxx, a cancer immunotherapy designed to treat over-express HER-2/neu receptor. In a Ph 1 study, HER-Vaxx stimulated potent polyclonal antibody response to HER-2/neu. HER-Vaxx is ready for Phase 1b/2 study in patients with gastric cancer

Visit: http://www.imugene.com/
Connect with Imugene on partnering360®

Biotech Showcase™ 2016
INanoBio Inc
INanoBio Inc
Tempe, Arizona, United States
Developing a low-cost high-accuracy nanopore sequencer capable of sequencing the whole genome in 15 minutes for $100. Our proprietary nanopore-transistor combines field effect...


Share this:Email this pageShare this on LinkedInShare this on Twitter

INanoBio Inc

INanoBio Inc is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 11:00 am. Room Davidson.
INanoBio Inc
Track: E
City: Tempe
State: Arizona
Country: United States
Ownership: Private
Developing a low-cost high-accuracy nanopore sequencer capable of sequencing the whole genome in 15 minutes for $100. Our proprietary nanopore-transistor combines field effect sensing with nanopore technology. In addition to medicine, it will have transformative impact on food production, synthetic biology and alternate energy. Raising $10 M in Series A.

Visit: http://www.inanobio.com/index.php
Connect with INanoBio Inc on partnering360®

Biotech Showcase™ 2016
Indi Molecular
Indi Molecular
Culver City, California, United States
Indi Molecular is a preclinical company developing protein catalyzed capture agent technology: a breakthrough process that produces very small, synthetic peptide molecules cap...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Indi Molecular

Indi Molecular is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 11:15 am. Room Davidson.
Indi Molecular
Track: E
City: Culver City
State: California
Country: United States
Ownership: Private
Indi Molecular is a preclinical company developing protein catalyzed capture agent technology: a breakthrough process that produces very small, synthetic peptide molecules capable of binding interactions that are equivalent or superior to monoclonal antibodies. PCCs have numerous advantages over antibodies: superb selectivity, high binding affinity, fully synthetic composition and low molecular weight.

Visit: http://www.indimolecular.com
Connect with Indi Molecular on partnering360®

Biotech Showcase™ 2016
Induce Biologics Inc
Induce Biologics Inc
Toronto, Ontario, Canada
Induce Biologics develops bone regeneration products. Our first product URIST™, is a patented BMP containing implant which in preclinical studies using less BMP makes more b...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Induce Biologics Inc

Induce Biologics Inc is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 8:45 am. Room Hearst.
Induce Biologics Inc
Track: A
City: Toronto
State: Ontario
Country: Canada
Ownership: Private
Induce Biologics develops bone regeneration products. Our first product URIST™, is a patented BMP containing implant which in preclinical studies using less BMP makes more bone than currently approved implants. GLP studies to date show URIST is safe and effective. We intend to initiate pilot clinical trials in 2016

Visit: http://www.inducebiologics.com
Connect with Induce Biologics Inc on partnering360®

Biotech Showcase™ 2016
Inivata Limited
Inivata Limited
Cambridge, United Kingdom
Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating tumor DNA (ctDNA) analysis to provide oncologists with the molecular information...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Inivata Limited

Inivata Limited is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 8:30 am. Room Hearst.
Inivata Limited
Track: A
City: Cambridge
Country: United Kingdom
Ownership: Private
Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating tumor DNA (ctDNA) analysis to provide oncologists with the molecular information necessary to guide more personalized treatment options and improve the outcomes of patients with cancer. More information is available at our website www.inivata.com

Visit: http://www.inivata.com/
Connect with Inivata Limited on partnering360®

Biotech Showcase™ 2016
Innokeys
Innokeys
Singapore, Singapore, Singapore
Innokeys is a Singapore based biopharmaceutical company that specializes in the development and commercialization of nimotuzumab - a humanized monoclonal antibody targeting th...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Innokeys

Innokeys is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 11:45 am. Room Hearst.
Innokeys
Track: A
City: Singapore
State: Singapore
Country: Singapore
Ownership: Private
Innokeys is a Singapore based biopharmaceutical company that specializes in the development and commercialization of nimotuzumab - a humanized monoclonal antibody targeting the Epidermal Growth Factor Receptor. Nimotuzumab is approved in 30 non-ICH countries for the treatment of several cancer indications and has an orphan designation in Europe and U.S.

Visit: http://www.innokeys.com
Connect with Innokeys on partnering360®

Biotech Showcase™ 2016
Inovio Pharmaceuticals
Inovio Pharmaceuticals
(NASDAQ:INO)
Plymouth Meeting, Pennsylvania, United States
Inovio is developing DNA-based immunotherapies to prevent and treat cancers and infectious diseases. Our DNA plasmid technology, which can encode for multiple antigens, has ac...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Inovio Pharmaceuticals

Inovio Pharmaceuticals is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 9:30 am. Room Mission I.
Inovio Pharmaceuticals
Track: B
City: Plymouth Meeting
State: Pennsylvania
Country: United States
Ownership: Public
Ticker: INO
Stock exchange: NASDAQ
Inovio is developing DNA-based immunotherapies to prevent and treat cancers and infectious diseases. Our DNA plasmid technology, which can encode for multiple antigens, has achieved best-in-class T cell generation correlated to efficacy, as published in The Lancet. Our products can function as monotherapies or in combination with other immuno-oncology technologies.

Visit: http://www.inovio.com
Connect with Inovio Pharmaceuticals on partnering360®

Biotech Showcase™ 2016
InSilico Medicine, Inc
InSilico Medicine, Inc
Baltimore, Maryland, United States
Insilico Medicine utilizes deep learning techniques on massive multi-omics data for scoring clinical trials, drug discovery, repurposing for aging and age-related diseases. Th...


Share this:Email this pageShare this on LinkedInShare this on Twitter

InSilico Medicine, Inc

InSilico Medicine, Inc is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 5:15 pm. Room Hearst.
InSilico Medicine, Inc
Track: A
City: Baltimore
State: Maryland
Country: United States
Ownership: Private
Insilico Medicine utilizes deep learning techniques on massive multi-omics data for scoring clinical trials, drug discovery, repurposing for aging and age-related diseases. The company provides a broad range of bioinformatics services to academia, pharmaceutical companies and hedge funds and aggregates and harmonizes large databases and pursues internal research programs.

Visit: http://www.InsilicoMedicine.com
Connect with InSilico Medicine, Inc on partnering360®

Biotech Showcase™ 2016
Intec Pharma
Intec Pharma
(NASDAQ:NTEC)
Jerusalem, Israel
A clinical stage biopharmaceutical company focused on developing drugs based on its proprietary oral drug delivery system - the Accordion Pill - that is designed to improve th...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Intec Pharma

Intec Pharma is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 10:30 am. Room Powell.
Intec Pharma
Track: D
City: Jerusalem
Country: Israel
Ownership: Public
Ticker: NTEC
Stock exchange: NASDAQ
A clinical stage biopharmaceutical company focused on developing drugs based on its proprietary oral drug delivery system - the Accordion Pill - that is designed to improve the efficacy and safety of existing drugs and drugs in development. Its leading product, for the treatment of PD symptoms, is entering P3.

Visit: http://www.intecpharma.com
Connect with Intec Pharma on partnering360®

Biotech Showcase™ 2016
Integene
Integene
Miami, Florida, United States
Integene is developing a patented platform gene therapy technology capable of regenerating vasculature to treat a broad range of vascular diseases, including peripheral arteri...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Integene

Integene is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 4:30 pm. Room Davidson.
Integene
Track: E
City: Miami
State: Florida
Country: United States
Ownership: Private
Integene is developing a patented platform gene therapy technology capable of regenerating vasculature to treat a broad range of vascular diseases, including peripheral arterial disease, critical limb ischemia (CLI), coronary artery disease, and other vascular disorders. Integene is focusing first on CLI, a potential Orphan indication with unmet medical need.

Visit: http://www.integene-int.com
Connect with Integene on partnering360®

Biotech Showcase™ 2016
Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc.
(NASDAQ:IPCI)
Toronto, Ontario, Canada
We are a pharmaceutical company specializing in research and development of novel and generic controlled-release and targeted-release oral solid dosage drugs. Our lead product...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc. is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 3:00 pm. Room Mission I.
Intellipharmaceutics International Inc.
Track: B
City: Toronto
State: Ontario
Country: Canada
Ownership: Public
Ticker: IPCI
Stock exchange: NASDAQ
We are a pharmaceutical company specializing in research and development of novel and generic controlled-release and targeted-release oral solid dosage drugs. Our lead product candidate (Rexista OxycodoneXR) is an Abuse Deterrent formulation of Oxycodone. Rexista has FDA Fast Track designation and we plan to file an NDA in Q2 2016.

Visit: http://www.intellipharmaceutics.com/
Connect with Intellipharmaceutics International Inc. on partnering360®

Biotech Showcase™ 2016
Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc.
Westport, Connecticut, United States
Intensity Therapeutics’ mission is to greatly extend the lives of patients with cancer. The Company is using its proprietary DfuseRxSM platform technology to create novel im...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 2:00 pm. Room Hearst.
Intensity Therapeutics, Inc.
Track: A
City: Westport
State: Connecticut
Country: United States
Ownership: Private
Intensity Therapeutics’ mission is to greatly extend the lives of patients with cancer. The Company is using its proprietary DfuseRxSM platform technology to create novel immune-based therapeutic products for a new and emerging field of cancer treatment known as in situ vaccination.

Visit: http://www.intensitytherapeutics.com
Connect with Intensity Therapeutics, Inc. on partnering360®

Biotech Showcase™ 2016
Interface Biologics, Inc.
Interface Biologics, Inc.
Toronto, Ontario, Canada
Interface Biologics, Inc. (IBI) is a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the safety and efficac...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Interface Biologics, Inc.

Interface Biologics, Inc. is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 9:30 am. Room Hearst.
Interface Biologics, Inc.
Track: A
City: Toronto
State: Ontario
Country: Canada
Ownership: Private
Interface Biologics, Inc. (IBI) is a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the safety and efficacy of medical devices. Our primary technology focus areas are 1) surface modifying macro-molecules and 2) polymer enabled drug delivery devices.

Visit: http://www.interfacebiologics.com
Connect with Interface Biologics, Inc. on partnering360®

Biotech Showcase™ 2016
InVivo Therapeutics
InVivo Therapeutics
(NASDAQ:NVIV)
Cambridge, Massachusetts, United States
InVivo Therapeutics is a company dedicated to redefining the life of the spinal cord injury (SCI) patient through the development of effective SCI therapies. InVivo is current...


Share this:Email this pageShare this on LinkedInShare this on Twitter

InVivo Therapeutics

InVivo Therapeutics is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 3:30 pm. Room Mission I.
InVivo Therapeutics
Track: B
City: Cambridge
State: Massachusetts
Country: United States
Ownership: Public
Ticker: NVIV
Stock exchange: NASDAQ
InVivo Therapeutics is a company dedicated to redefining the life of the spinal cord injury (SCI) patient through the development of effective SCI therapies. InVivo is currently running the INSPIRE pivotal probable benefit study of its Neuro-Spinal Scaffold in acute thoracic SCI and has reported encouraging results in pilot patients.

Visit: http://www.invivotherapeutics.com
Connect with InVivo Therapeutics on partnering360®

Biotech Showcase™ 2016
ISA Pharmaceuticals
ISA Pharmaceuticals
Leiden, Netherlands
ISA Pharmaceuticals is a Netherlands based clinical stage company. It develops rationally designed immunotherapeutics against cancer and persistent viral infections. ISA’s p...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ISA Pharmaceuticals

ISA Pharmaceuticals is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 2:15 pm. Room Hearst.
ISA Pharmaceuticals
Track: A
City: Leiden
Country: Netherlands
Ownership: Private
ISA Pharmaceuticals is a Netherlands based clinical stage company. It develops rationally designed immunotherapeutics against cancer and persistent viral infections. ISA’s platform is based on proprietary SLP® (synthetic-long-peptide) and AMPLIVANT® (adjuvant) technologies and applicable to multiple targets, including clinically validated HPV16 antigens, Hepatitis B antigens and personal mutation-derived neo-antigens.

Visit: http://www.isa-pharma.com
Connect with ISA Pharmaceuticals on partnering360®

Biotech Showcase™ 2016
Isarna Therapeutics
Isarna Therapeutics
Munich, Germany
Isarna Therapeutics is a clinical stage privately held company developing selective TGF-β inhibitors to effectively treat ophthalmic and fibrotic diseases and fight cancer. I...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Isarna Therapeutics

Isarna Therapeutics is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 9:15 am. Room Hearst.
Isarna Therapeutics
Track: A
City: Munich
Country: Germany
Ownership: Private
Isarna Therapeutics is a clinical stage privately held company developing selective TGF-β inhibitors to effectively treat ophthalmic and fibrotic diseases and fight cancer. Isarna is advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

Visit: http://www.isarna-therapeutics.com
Connect with Isarna Therapeutics on partnering360®

Biotech Showcase™ 2016
Ischemix, Inc.
Ischemix, Inc.
Maynard, Massachusetts, United States
Ischemix’ lead candidate, a novel cytoprotective compound, is in a Phase 2 trial to prevent contrast-induced acute kidney injury, a leading form of hospital-acquired acute k...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Ischemix, Inc.

Ischemix, Inc. is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 9:00 am. Room Davidson.
Ischemix, Inc.
Track: E
City: Maynard
State: Massachusetts
Country: United States
Ownership: Private
Ischemix’ lead candidate, a novel cytoprotective compound, is in a Phase 2 trial to prevent contrast-induced acute kidney injury, a leading form of hospital-acquired acute kidney injury (HA-AKI). HA-AKI, which has no currently available drug therapies, is estimated to afflict approximately three million patients and cause 700,000 deaths worldwide annually.

Visit: http://www.ischemix.com
Connect with Ischemix, Inc. on partnering360®

Biotech Showcase™ 2016
Ixchel Pharma, LLC
Davis, California, United States
Ixchel Pharma is a preclinical stage company focused on mitochondrial orphan disease and diabetes. Ixchel repurposes drugs and identify NCEs for mitochondrial diseases: Friedr...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Ixchel Pharma, LLC

Ixchel Pharma, LLC is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 9:00 am. Room Hearst.
Track: A
City: Davis
State: California
Country: United States
Ownership: Private
Ixchel Pharma is a preclinical stage company focused on mitochondrial orphan disease and diabetes. Ixchel repurposes drugs and identify NCEs for mitochondrial diseases: Friedreich's ataxia, LHON, and mitochondrial obesity and diabetes, which rescue pathology in animal models, and are already known to be safe in humans.

Visit: http://www.ixchelpharma.com
Connect with Ixchel Pharma, LLC on partnering360®

Biotech Showcase™ 2016
Izun Pharmaceuticals
Trumbull, Connecticut, United States
Izun Pharmaceuticals is an innovative clinical stage biotechnology company that specializes in topical therapy which generates a rapid & profound resolution of inflammatory di...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Izun Pharmaceuticals

Izun Pharmaceuticals is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 3:00 pm. Room Davidson.
Track: E
City: Trumbull
State: Connecticut
Country: United States
Ownership: Private
Izun Pharmaceuticals is an innovative clinical stage biotechnology company that specializes in topical therapy which generates a rapid & profound resolution of inflammatory diseases that effect mucosal & dermal tissues using botanically derived pharmaceutical ingredients. Izun is focused on the large market opportunities of chemotherapeutic mucositis, wound healing and atrophic vaginitis.

Visit: http://www.izunpharma.com
Connect with Izun Pharmaceuticals on partnering360®

Biotech Showcase™ 2016
Kalos Therapeutics, Inc.
Kalos Therapeutics, Inc.
San Diego, California, United States
Kalos therapeutics is a late stage Preclinical company with three programs based on NCE's similar to peptides found in the heart Kidneys and the Shins. Kalos controls cancer a...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Kalos Therapeutics, Inc.

Kalos Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 10:00 am. Room Davidson.
Kalos Therapeutics, Inc.
Track: E
City: San Diego
State: California
Country: United States
Ownership: Private
Kalos therapeutics is a late stage Preclinical company with three programs based on NCE's similar to peptides found in the heart Kidneys and the Shins. Kalos controls cancer and related comorbidities without Chemotoxic side effects and puts tumors into a sustained non dividing state.

Visit: http://www.kalostpx.com
Connect with Kalos Therapeutics, Inc. on partnering360®

Biotech Showcase™ 2016
Karus Therapeutics Ltd.
Karus Therapeutics Ltd.
ABINGDON, United Kingdom
Karus is a leader in the design and development of innovative small-molecule drugs that combine targeted therapy and immunotherapy for the effective treatment of a diverse ran...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Karus Therapeutics Ltd.

Karus Therapeutics Ltd. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 2:30 pm. Room Hearst.
Karus Therapeutics Ltd.
Track: A
City: ABINGDON
Country: United Kingdom
Ownership: Private
Karus is a leader in the design and development of innovative small-molecule drugs that combine targeted therapy and immunotherapy for the effective treatment of a diverse range of solid and hematological cancers. The company's development programs are built on an exceptional knowledge of PI3K- and HDAC-isoform biology and function.

Visit: http://www.karustherapeutics.com
Connect with Karus Therapeutics Ltd. on partnering360®

Biotech Showcase™ 2016
Kitov Pharmaceuticals Ltd.
Kitov Pharmaceuticals Ltd.
(NASDAQ/TASE:KTOV)
Tel Aviv, Israel
Kitov is a pharmaceutical company developing therapeutic candidates for the simultaneous treatment of two clinical conditions: pain caused by osteoarthritis andhypertension, w...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Kitov Pharmaceuticals Ltd.

Kitov Pharmaceuticals Ltd. is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 5:00 pm. Room Market Street.
Kitov Pharmaceuticals Ltd.
Track: F
City: Tel Aviv
Country: Israel
Ownership: Public
Ticker: KTOV
Stock exchange: NASDAQ/TASE
Kitov is a pharmaceutical company developing therapeutic candidates for the simultaneous treatment of two clinical conditions: pain caused by osteoarthritis andhypertension, which can be pre-existing or caused by the treatment for osteoarthritis. In December 2015 we announced succesful results of our phase III clinical trial for our first product, KIT-302.

Visit: http://kitovpharma.com
Connect with Kitov Pharmaceuticals Ltd. on partnering360®

Biotech Showcase™ 2016
KPI Therapeutics
KPI Therapeutics
Seattle, Washington, United States
KPI Therapeutics leads an alliance of development partners through a virtual paradigm that drives focused and efficient drug development of game changing platforms with first ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

KPI Therapeutics

KPI Therapeutics is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 2:45 pm. Room Davidson.
KPI Therapeutics
Track: E
City: Seattle
State: Washington
Country: United States
Ownership: Private
KPI Therapeutics leads an alliance of development partners through a virtual paradigm that drives focused and efficient drug development of game changing platforms with first in class autoimmune diseases and chronic pain.

Visit: http://www.kpitherapeutics.com/

Biotech Showcase™ 2016
Lakewood Amedex Inc
Lakewood Amedex Inc
Sarasota, Flordia, United States
Lakewood-Amedex's product portfolio consists of a new class of anti-bacterials more effective than antibiotics, also anti-virals and potential therapies for acute and chronic ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Lakewood Amedex Inc

Lakewood Amedex Inc is scheduled to present at Biotech Showcase™ 2016
Wednesday, January 13 at 9:30 am. Room Davidson.
Lakewood Amedex Inc
Track: E
City: Sarasota
State: Flordia
Country: United States
Ownership: Private
Lakewood-Amedex's product portfolio consists of a new class of anti-bacterials more effective than antibiotics, also anti-virals and potential therapies for acute and chronic human diseases. Lakewood’s IP portfolio contains 74 issued patents and 13 patent filings covering its products/technologies in major pharmaceutical markets. Company is initiating Phase I/IIa clinical trial.

Visit: http://www.lakewoodamedex.com
Connect with Lakewood Amedex Inc on partnering360®

Biotech Showcase™ 2016
Leading Biosciences Inc
Leading Biosciences Inc
Solana Beach, California, United States
Leading BioSciences is a clinical-stage, pharmaceutical company. Our lead product is a therapeutic currently in Phase 2 clinical trials to treat three common forms of acute sh...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Leading Biosciences Inc

Leading Biosciences Inc is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 10:00 am. Room Davidson.
Leading Biosciences Inc
Track: E
City: Solana Beach
State: California
Country: United States
Ownership: Private
Leading BioSciences is a clinical-stage, pharmaceutical company. Our lead product is a therapeutic currently in Phase 2 clinical trials to treat three common forms of acute shock and multi-organ failure: cardiogenic shock following heart surgery, septic shock and hemorrhagic shock. Currently raising a $20M Series C round.

Visit: http://leadingbiosciences.com
Connect with Leading Biosciences Inc on partnering360®

Biotech Showcase™ 2016
Linus Oncology, Inc.
Linus Oncology, Inc.
Miami, Florida, United States
Linus Oncology owns commercialization rights and patents to the Indenoisoquinolines, SUCCESSOR agents to the Camptothecins. The NCI completed 2 phase I trials, clearly demonst...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Linus Oncology, Inc.

Linus Oncology, Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 1:45 pm. Room Davidson.
Linus Oncology, Inc.
Track: E
City: Miami
State: Florida
Country: United States
Ownership: Private
Linus Oncology owns commercialization rights and patents to the Indenoisoquinolines, SUCCESSOR agents to the Camptothecins. The NCI completed 2 phase I trials, clearly demonstrating safety and effectiveness. Linus has a cross license from NCI for phase II corporate studies.

Visit: http://www.linusoncology.com
Connect with Linus Oncology, Inc. on partnering360®

Biotech Showcase™ 2016
Lipocalyx
Lipocalyx
Halle, Germany
Lipocalyx is a drug delivery firm specialized in nucleic acid delivery. Our Viromer(R) platform is in preclinical stage and is currently tested by leading developers of mRNA a...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Lipocalyx

Lipocalyx is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 5:15 pm. Room Davidson.
Lipocalyx
Track: E
City: Halle
Country: Germany
Ownership: Private
Lipocalyx is a drug delivery firm specialized in nucleic acid delivery. Our Viromer(R) platform is in preclinical stage and is currently tested by leading developers of mRNA and genetic therapies.

Visit: http://www.viromer-transfection.com
Connect with Lipocalyx on partnering360®

Biotech Showcase™ 2016
Lung Therapeutics, Inc.
Lung Therapeutics, Inc.
Austin, Texas, United States
Lung Therapeutics is a preclinical-stage biotechnology company that leverages validated drug programs to develop first in class therapies for unmet needs in lung injury and di...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Lung Therapeutics, Inc.

Lung Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 3:00 pm. Room Hearst.
Lung Therapeutics, Inc.
Track: A
City: Austin
State: Texas
Country: United States
Ownership: Private
Lung Therapeutics is a preclinical-stage biotechnology company that leverages validated drug programs to develop first in class therapies for unmet needs in lung injury and disease, with a focus on orphan or niche indications. These include pleural disease, acute lung injury, and idiopathic pulmonary fibrosis.

Visit: http://www.lungtx.com
Connect with Lung Therapeutics, Inc. on partnering360®

Biotech Showcase™ 2016
Lytix Biopharma
Oslo, Norway
Lytix Biopharma is a clinical stage company focusing on development of new cancer immunotherapies. Its lead product LTX-315, a first in class oncolytic peptide immunotherapy, ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Lytix Biopharma

Lytix Biopharma is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 3:15 pm. Room Hearst.
Track: A
City: Oslo
Country: Norway
Ownership: Private
Lytix Biopharma is a clinical stage company focusing on development of new cancer immunotherapies. Its lead product LTX-315, a first in class oncolytic peptide immunotherapy, is currently in phase I for the treatment of solid tumors and in preparation for phase I/II combination trials with checkpoint inhibitors.

Visit: http://www.lytixbiopharma.com
Connect with Lytix Biopharma on partnering360®

Biotech Showcase™ 2016
Macrolide Pharmaceuticals
Macrolide Pharmaceuticals
Lexington, Massachusetts, United States
Macrolide Pharmaceuticals extends the anti-bacterial spectrum of macrolide antibiotics based on novel chemistry developed by Prof. Andrew Myers of Harvard. This technology ena...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Macrolide Pharmaceuticals

Macrolide Pharmaceuticals is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 3:00 pm. Room Davidson.
Macrolide Pharmaceuticals
Track: E
City: Lexington
State: Massachusetts
Country: United States
Ownership: Private
Macrolide Pharmaceuticals extends the anti-bacterial spectrum of macrolide antibiotics based on novel chemistry developed by Prof. Andrew Myers of Harvard. This technology enables complete synthesis of macrolides, compared to semi-synthetic approaches, allowing synthesis of virtually any macrolide imaginable. Initial novel macrolides show promising results in Gram-negative bacteria.

Visit: http://www.macrolide.com
Connect with Macrolide Pharmaceuticals on partnering360®

Biotech Showcase™ 2016
Madison Vaccines Incorporated
Madison Vaccines Incorporated
Madison, Wisconsin, United States
MVI is developing two DNA vaccines to treat prostate cancer. MVI-816 is in a multi-site Phase 2 trial in non-metastatic, biochemically recurrent prostate cancer and in a Phase...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Madison Vaccines Incorporated

Madison Vaccines Incorporated is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 8:15 am. Room Davidson.
Madison Vaccines Incorporated
Track: E
City: Madison
State: Wisconsin
Country: United States
Ownership: Private
MVI is developing two DNA vaccines to treat prostate cancer. MVI-816 is in a multi-site Phase 2 trial in non-metastatic, biochemically recurrent prostate cancer and in a Phase 1/2 trial in combination with Keytruda®, in men with metastatic, castrate-resistant prostate cancer. MVI-118 (Phase 1) is in metastatic patients initiating ADT.

Visit: http://www.madisonvaccines.com
Connect with Madison Vaccines Incorporated on partnering360®

Biotech Showcase™ 2016
Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc.
(OTCQB:MTNB)
Bedminster, New Jersey, United States
Developing safe and effective broad spectrum therapeutics to treat serious, life-threatening infections. Its proprietary, disruptive technology utilizes lipid-crystal nano-par...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc. is scheduled to present at Biotech Showcase™ 2016
Tuesday, January 12 at 2:30 pm. Room Powell.
Matinas BioPharma Holdings, Inc.
Track: D
City: Bedminster
State: New Jersey
Country: United States
Ownership: Public
Ticker: MTNB
Stock exchange: OTCQB
Developing safe and effective broad spectrum therapeutics to treat serious, life-threatening infections. Its proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. A Phase 2a trial of MAT2203 for refractory mucocutaneous candidiasis is expected to commence during 1Q16.

Visit: http://www.matinasbiopharma.com
Connect with Matinas BioPharma Holdings, Inc. on partnering360®

Biotech Showcase™ 2016
MaxCyte, Inc.
MaxCyte, Inc.
Gaithersburg, Maryland, United States
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Using a scalable el...


Share this:Email this pageShare this on LinkedInShare this on Twitter

MaxCyte, Inc.

MaxCyte, Inc. is scheduled to present at Biotech Showcase™ 2016
Monday, January 11 at 10:30 am. Room Davidson.
MaxCyte, Inc.
Track: E
City: Gaithersburg
State: Maryland
Country: United States
Ownership: Private
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Using a scalable electroporation process called Flow Transfection®, MaxCyte’s proprietary cell transfection platform is used by pharmaceutical and biotechnology companies around the world to engineer cells for a wide range of applications

Visit: http://www.maxcyte.com
Connect with MaxCyte, Inc. on partnering360®

Biotech Showcase™ 2016